# (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 10 May 2007 (10.05.2007)

(10) International Publication Number WO 2007/053573 A2

- (51) International Patent Classification: A61K 31/4412 (2006.01) A61P 35/00 (2006.01)
- (21) International Application Number:

PCT/US2006/042367

- (22) International Filing Date: 31 October 2006 (31.10.2006)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

60/731,597 31 October 2005 (31.10.2005)

- (71) Applicant (for all designated States except US): BAYER PHARMACEUTICALS CORPORATION [US/US]: 400 Morgan Lane, West Haven, Connecticut 06516-4175
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): WILHELM, Scott [US/US]; 255 Midland Drive, Orange, Connecticut 06477 (US).
- (74) Agents: TRAVERSO, Richard, J. et al.; Millen, White, Zelano & Branigan, P.C., 2200 Clarendon Boulevard, Suite 1400, Arlington, Virginia 22201 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Published:**

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: TREATMENT OF CANCER WITH SORAFENIB

(57) Abstract: The present invention provides compositions and methods for treating specific cancers with effective amounts of sorafenib.

#### TREATMENT OF CANCER WITH SORAFENIB

#### DESCRIPTION OF THE INVENTION

[0001] Cancer is a class of diseases characterized by two heritable properties: (1) uncontrolled cell division and (2) the ability of these cells to invade other tissues, either by direct growth into adjacent tissue (invasion) or by migration of cells to distant sites (metastasis). The hyper-proliferative properties initially give rise to a tumor or neoplasm. A tumor is only considered a cancer when its cells acquire the ability to invade surrounding tissues, e.g., by breaking loose and entering the blood or lymph systems, or by forming secondary tumors at other sites in the body. The unregulated growth is caused by damaged DNA, resulting in mutations to vital genes that control cell division, the cell cycle, among other functions. One or more of these mutations, which can be inherited or acquired, can lead to uncontrolled cell division and cancer.

[0002] Cancers can be classified according to the tissue and cell type from which they arise. Cancers developing from epithelial cells are called carcinomas, and those from connective and muscle cells are called sarcomas. Additional cancers include those arising from hematopoietic cells (e.g., leukemia) and cancers of the nervous system.

[0003] In general, cancers appear to arise during a process in which an initial population of abnormal cells evolve into more aberrant cells through successive cycles of mutation and selection. More than 100 different genes have been identified which, when mutant, result in cancer. These so-called cancer-critical genes fall into two broad classes: oncogenes and tumor suppressor genes. Many cancer-critical genes play a role in the regulation of cell divisions, a highly complicated process involving multiple and parallel pathways. These include growth factors, cytokines, hormones, etc.

[0004] Cancer can cause many different symptoms, depending on the site and character of the malignancy and whether there is metastasis. A definitive diagnosis usually requires the microscopic examination of tissue obtained by biopsy. Once diagnosed, cancer is usually treated with surgery, chemotherapy and/or radiation.

[0005] If untreated, most cancers eventually cause death. Cancer is one of the leading causes of death in developed countries. It is estimated by the National Cancer Institute that

approximately 9.8 million Americans were alive in January 2001 with a history of cancer. About 1,372,910 new cases of cancer were expected to be diagnosed in 2005, alone. In 2005, almost 600,000 Americans died of cancer, about 1 out of every 4 deaths. Many forms of cancer are associated with environmental factors, which may be avoidable. Smoking tobacco leads to more cancers than any other environmental factor.

[0006] The present invention provides methods of treating specific cancers in listed in Table 1, comprising, e.g., comprising administering to a subject in need thereof an effective amount of sorafenib, wherein the cancer is treated.

**[0007]** The phrase "effective amount" indicates the amount of sorafenib which is effective to treat any symptom or aspect of the specific cancer. Effective amounts can be determined routinely. Further guidance on dosages and administration regimens is provided below.

[0008] The term "treating" is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving, etc., one or more of the symptoms associated with a specific cancer mentioned herein in Table 1. Administering effective amounts of sorafenib can treat one or more aspects of the cancer disease, including, but not limited to, causing tumor regression; causing cell death; causing apoptosis; causing necrosis; inhibiting cell proliferation; inhibiting tumor growth; inhibiting tumor metastasis; inhibiting tumor migration; inhibiting tumor invasion; reducing disease progression; stabilizing the disease; reducing or inhibiting angiogenesis; prolonging patient survival; enhancing patient's quality of life; reducing adverse symptoms associated with cancer; and reducing the frequency, severity, intensity, and/or duration of any of the aforementioned aspects.

**[0009]** Any of the listed cancers can be treated in accordance of the present invention, irrespective of the cause of the cancer, and irrespective of the genetic lesions associated with it (see, e.g., Atlas of Genetics and Cytogenetics in Oncology and Haematology on the worldwide web at infobiogen.fr/services/chromcancer/ for an atlas of genes involved in cancer). Table 1 is a list of cancers that be treated with sorafenib.

[0010] Cancers which can be treated include, e.g., cancers which are primary; which arise from a primary tumor at a secondary metastatic site; which have been treated by surgery (e.g., entirely removed, surgical resection, etc); which have been treated by chemotherapy, radiation, radiofrequency ablation, and/or any other adjunct to drug therapy; which have acquired drug-resistance; which are refractory to a chemotherapeutic agent.

[0011] Any subject can be in accordance with the present invention, including, e.g., mammals, such as rats, mice, dogs, cats, horses, cows, goats, sheep, monkeys, and humans.

The term "sorafenib" as used herein refers to the tosylate salt of the compound N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea of the formula I below including all polymorphs, hydrates, solvates or combinations thereof. Formula I is as follows:

[0012] The compound N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea can be prepared by the following multistep procedure:

**[0013]** Step 1: Preparation of 4-chloro-2-pyridinecarboxamide

**[0014]** To a stirred mixture of methyl 4-chloro-2-pyridinecarboxylate hydrochloride (1.0 g, 4.81 mmol) dissolved in conc. aqueous ammonia (32 mL) is added ammonium chloride (96.2 mg, 1.8 mmol, 0.37 equiv.), and the heterogeneous reaction mixture is stirred at ambient temperature for 16h. The reaction mixture is poured into EtOAc (500 mL) and water (300 mL). The organic layer is washed with water (2 x 300 mL) and a saturated NaCl solution (1 x 300 mL), dried (MgSO<sub>4</sub>), concentrated in *vacuo* to give 4-chloro-2-pyridinecarboxamide as a beige solid (604.3 mg, 80.3%): TLC (50% EtOAc / hexane)  $R_f$  0.20;  $^1$ H-NMR (DMSO-d<sub>6</sub>)  $\delta$  8.61 (d, J = 5.4 Hz, 1H), 8.20 (broad s, 1H), 8.02 (d, J = 1.8 Hz, 1H), 7.81 (broad s, 1H), 7.76 to 7.73 (m, 1H).

[0015] Step 2: Preparation of 4-(4-aminophenoxy)-2-pyridinecarboxamide

$$H_2N$$
  $O$   $NH_2$ 

**[0016]** To 4-aminophenol (418 mg, 3.83 mmol) in anh DMF(7.7 mL) is added potassium *tert*-butoxide (447 mg, 3.98 mmol, 1.04 equiv.) in one portion. The reaction mixture is stirred at room temperature for 2 h, and a solution of 4-chloro-2-pyridinecarboxamide (600 mg, 3.83 mmol, 1.0 equiv.) in anh DMF (4 mL) is then added. The reaction mixture is stirred at 80 °C for 3 days and poured into a mixture of EtOAc and a saturated NaCl solution. The organic layer is sequentially washed with a saturated NH<sub>4</sub>Cl solution then a saturated NaCl solution, dried (MgSO<sub>4</sub>), and concentrated under reduced pressure. The crude product is purified using MPLC chromatography (Biotage<sup>®</sup>; gradient from 100% EtOAc to followed by 10% MeOH / 50% EtOAc / 40% hexane) to give the 4-chloro-5-trifluoromethylaniline as a brown solid (510 mg, 58%). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$  8.43 (d, J = 5.7 Hz, 1H), 8.07 (br s, 1H), 7.66 (br s, 1H), 7.31 (d, J = 2.7 Hz, 1H), 7.07 (dd, J = 5.7 Hz, 2.7 Hz, 1H), 6.85 (d, J = 9.0 Hz, 2 H), 6.62 (d, J = 8.7 Hz, 2H), 5.17 (broad s, 2H); HPLC EI-MS m/z 230 ((M+H)<sup>+</sup>.

[0017] Step 3: Preparation of N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-(4-pyridyloxy)]phenyl} urea

[0018] A mixture of 4-chloro-5-trifluoromethylaniline (451 mg, 2.31 mmol, 1.1 equiv.) and 1,1'-carbonyl diimidazole (419 mg, 2.54 mmol, 1.2 equiv.) in anh dichloroethane (5.5 mL) is stirred under argon at 65 °C for 16 h. Once cooled to room temperature, a solution of 4-(4-aminophenoxy)-2-pyridinecarboxamide (480 mg, 2.09 mmol) in anh THF (4.0 mL) is added, and the reaction mixture is stirred at 60°C for 4 h. The reaction mixture is poured into EtOAc, and the organic layer is washed with water (2x) and a saturated NaCl solution (1x), dried (MgSO<sub>4</sub>), filtered, and evaporated in *vacuo*. Purification using MPLC chromatography (Biotage<sup>®</sup>; gradient from 100% EtOAc to 2% MeOH / EtOAc) gave N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-(4-pyridyloxy)]phenyl} urea as a white solid (770 mg, 82%): TLC (EtOAc) R<sub>f</sub>

0.11, 100% ethyl acetate  $^{1}$ H-NMR (DMSO-d<sub>6</sub>)  $\delta$  9.21 (s, 1H), 8.99 (s, 1H), 8.50 (d, J = 5.6 Hz, 1H), 8.11 (s, 1H), 8.10 (s, 1H), 7.69 (broad s, 1H), 7.64 (dd, J = 8.2 Hz, 2.1 Hz, 1H), 7.61 (s, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.39 (d, J = 2.5 Hz, 1H), 7.15 (d, J = 8.9 Hz, 2H), 7.14 (m, 1H); MS LC-MS (MH<sup>+</sup> = 451). Anal. calcd for  $C_{20}H_{14}ClF_{3}N_{4}O_{3}$ : C 53.29% H 3.13% N 12.43%. Found: C 53.33% H 3.21% N 12.60%.

**[0019]** Other methods of preparing N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-(4-pyridyloxy)]phenyl} urea are described in Bankston et al. "A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer" Org. Proc. Res. Dev. 2002, 6(6), 777-781, and WO 00/42012 and WO 00/41698.

[0020] An example of the preparation of sorafenib in the polymorph II is s follows:

[**0021**] 903 g of 4-{4-[({[4-chloro-3-

(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, prepared as described above, are initially charged in 2700 ml of ethanol. 451.7 g of ptoluenesulfonic acid monohydrate are dissolved in 1340 g of ethanol and added dropwise at room temperature. The suspension is stirred at room temperature for 1 hour, then filtered off with suction, and the residue is washed three times with 830 ml each time of ethanol. The drying is effected at 50°C under reduced pressure with supply of air. 1129.6 g of the title compound in the polymorph II are obtained.

[0022] An example of the preparation of sorafenib in the polymorph I is as follows:

[0023] Heating 5mg of "Sorafenib," [tosylate salt of 4-{4-[({[4-chloro-3-

(trifluoromethyl)phenyl]amino}carbonyl)amino]-phenoxy}-N-methylpyridine-2-carboxamide] in the polymorph II to 200°C at a heating rate of 20°C/min and subsequently cooling to room temperature at a cooling rate of 2°C/min. The sample is tested thermoanalytically (DSC) and corresponds to the title compound in the polymorph I.

[0024] The specific dose level and frequency of dosage may vary, depending upon a variety of factors, including the activity of the active agent, its metabolic stability and length of action, rate of excretion, mode and time of administration, the age, body weight, health condition, gender, diet, baseline hematologic and biologic parameters (e.g., WBCs, granulocytes, platelets, hemoglobin, creatinine, bilirubin, albumin, etc.), etc., of the subject, and the severity, intensity,

stage of the cancer, primary site of cancer, size of cancer lesion, presence or extent of metastases, surgical status, disease progression (i.e., aggressive), etc. of the disease.

[0025] The compound of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, spray, inhalation, subcutaneous, intravenous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, intrathecal, intratumoral, etc. Sorafenib can be administered directly to the site of a tumor, either pre- or post-operatively. It can be administered alone, or in combination with any ingredient(s), active or inactive.

[0026] Sorafenib can be administered by the oral route using the pharmaceutical composition of the present invention will generally range, based on body weight, from about 0.01 mg/kg to about 50 mg/kg; from about 1 mg/kg to about 40 mg/kg; from about 5 mg/kg to about 30 mg/kg; from about 10 to about 25 mg/kg; about 10 mg/kg; about 20 mg/kg; about 25 mg/kg; about 30 mg/kg; etc.

[0027] Any suitable dosing interval can be used in accordance with the present invention. For example, the compound can be administered once, twice (BID), three, four, etc., times a day. For example, about 100, about 200, about 400 mg, about 500 mg, about 600 mg, or about 800 mg can be administered one, twice, or three times daily.

**[0028]** Sorafenib can be administered at any suitable time. For example, it can be administered routinely as other chemotherapeutic agents; it can be administered as a bolus prior to a surgical intervention; prior to or after radiation, radiofrequency ablation and other energy treatments; post-operatively; pre-operatively; etc.

[0029] Sorafenib can be further combined with any other suitable additive or pharmaceutically acceptable carrier. Such additives include any of those used conventionally, such as those described in Remington: The Science and Practice of Pharmacy (Gennaro and Gennaro, eds, 20th edition, Lippincott Williams & Wilkins, 2000); Theory and Practice of Industrial Pharmacy (Lachman et al., eds., 3rd edition, Lippincott Williams & Wilkins, 1986); Encyclopedia of Pharmaceutical Technology (Swarbrick and Boylan, eds., 2nd edition, Marcel Dekker, 2002).

[0030] The compounds can be in any suitable form, without limitation. Forms suitable for oral use, include, but are not limited to, tablets, troches, lozenges, aqueous or oily suspensions,

dispersible powders or granules, emulsions, hard or soft capsules, solutions, syrups and elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.

[0031] Compounds can be formulated with other ingredients, e.g., "pharmaceutically acceptable carriers" or "excipients" to indicate they are combined with the active drug and can be administered safely to a subject for therapeutic purposes. These include, but are not limited to, antioxidants, preservatives, dyes, tablet-coating compositions, plasticizers, inert carriers, excipients, polymers, coating materials, osmotic barriers, devices and agents which slow or retard solubility, etc.

[0032] Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.

**[0033]** Non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc.

**[0034]** Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

[0035] Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide

with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

**[0036]** Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

[0037] The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0038] Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

[0039] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

[0040] The compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These compositions can be prepared by mixing the drug with

a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature or vaginal temperature and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.

[0041] Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; "Transdermal Controlled Systemic Medications"; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 3Mar94). For example, a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.

Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane. Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.

[0043] Suitable penetration enhancing materials for transdermal delivery system are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C8–C18 fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C8–C18 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl

isosorbid and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C8–C18 fatty alcohols, saturated or unsaturated C8–C18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated discarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.

**[0044]** Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.

[0045] Compositions comprising precursors can also be formulated for controlled release, where release of the active ingredient is regulated or modulated to achieve a desired rate of delivery into the systemic circulation. A controlled release formulation can be pulsed, delayed, extended, slow, steady, immediate, rapid, fast, etc. It can comprise one or more release formulations, e.g. extended- and immediate- release components. Extended delivery systems can be utilized to achieve a dosing internal of once every 24 hours, once every 12 hours, once every 8 hours, once every 6 hours, etc. The dosage form/delivery system can be a tablet or a capsule suited for extended release, but a sustained release liquid or suspension can also be used. A controlled release pharmaceutical formulation can be produced which maintains the release of, and or peak blood plasma levels of sorafenib.

**[0046]** Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsœver.

**[0047]** From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

### Table 1

-A-

Adenocarcinoma Adenocarcinoma Lung Cancer Adenocystic Carcinoma Adenoid Cystic Breast Cancer Adenoid Cystic Carcinoma

### **Adrenal Gland Cancer:**

Adrenal Gland Cancer - Cortical Adenoma Adrenal Gland Cancer - Cortical Carcinoma

#### AIDS related disorders:

AIDS-related disorders - Kaposi's sarcoma AIDS-related disorders, - lymphoma

Advanced Breast Cancer Aggressive Breast Cancer Ameloblastoma

### Anal (Anus) Cancer, including:

Anal Cancer - Early-Stage (Superficial)

Anal Cancer - Intermediate-Stage I

Anal Cancer - Intermediate-Stage II

Anal Cancer - Intermediate-Stage III

Anal Cancer - Metastatic, Advanced-Stage IV

Anal Cancer - Adenocarcinomas

Anal Cancer - Intraepithelial Neoplasia

Anal Cancer - Bowen's Disease

Anal Cancer - Paget's Disease

Anal Cancer - Small Cell Cancers

Anal Cancer - Squamous Cell Carcinoma

Angiosarcoma Appendix Cancer (Appendiceal Cancer) Ascites, Malignant Astrocytoma

-B-

Barrett's Esophagus
Bartholin Gland Cancer
Basal Cell Carcinoma
Basal Cell Skin Cancer
B-Cell Lymphoma
Bilateral Breast Cancer
Bile Duct Cancer

#### Bladder Cancer:

Bladder Cancer - Superficial

Bladder Cancer - Muscle-Invasive

Bladder Cancer - Small Cell

Bladder Cancer - Metastases

### **Bone Cancer:**

Bone Cancer - Chordoma

Bone Cancer - Chondrosarcoma

Bone Cancer - Ewing's Sarcoma (Child)

Bone Cancer - Giant Cell

Bone Cancer - Mesenchymal Chondrosarcoma

Bone Cancer - Osteosarcoma

Bone Cancer - Bone Marrow Transplantation

Bone Cancer - Bone Metastases

# Bowen's Disease

# **Borderline Ovarian Cancer**

## **Brain Tumors:**

Brain Tumors - Adult

Brain Tumors - Child

Brain Tumors - Astrocytoma

Brain Tumors - Brainstem

Brain Tumors - Cavernous Sinus

Brain Tumors - Chondroma

Brain Tumors - Ependymoma

Brain Tumors - Glioblastoma

Brain Tumors - Glioma

Brain Tumors - Gliomatosis

Brain Tumors - Hemangiopericytoma

Brain Tumors - Medulloblastoma

Brain Tumors - Oligodendroglioma

Brain Tumors - Pineoblastoma / Pinealoma

Brain Tumors - Primary Central Nervous System Lymphoma

Brain Tumors - Thalamic

Brain Tumors - Brainstem Glioma

# **Breast Cancers** Including:

Breast Cancer - Adenoid Cystic

Breast Cancer - Advanced

Breast Cancer - Aggressive

Breast Cancer - Apocrine Carcinoma

Breast Cancer - Bilateral (in both breasts)

Breast Cancer - Comedo Type

Breast Cancer - Ductal Carcinoma In Situ

Breast Cancer - Ductal Carcinoma Invasive

Breast Cancer - Early Stage

Breast Cancer - Estrogen-Negative

Breast Cancer - High-Risk

Breast Cancer - Inflammatory

Breast Cancer - in Pregnancy

Breast Cancer - Lobular, Invasive

Breast Cancer - Lobular Carcinoma In situ (LCIS)

Breast Cancer - Lymphoma

Breast Cancer - Medullary

Breast Cancer - Microinvasive

Breast Cancer - Mucinous

Breast Cancer - Node-Negative

Breast Cancer - Node-Positive

Breast Cancer, Nonepithelial Neoplasms:

Breast Cancer - Nonepithelial Neoplasms - Phyllodes Sarcomas

Breast Cancer - Nonepithelial Neoplasms - Phyllodes Tumors

Breast Cancer - Occult with Lymphatic Metastasis

Breast Cancer - Papillary

Breast Cancer - Postmenopausal

Breast Cancer - Premenopausal

Breast Cancer - Recurrent

Breast Cancer - Sarcoma

Breast Cancer - Secretory (juvenile) Carcinoma

Breast Cancer - Squamous

Breast Cancer - Stage I

Breast Cancer - Stage II

Breast Cancer - Stage III

Breast Cancer - Stage IV

Breast Cancer - Tubular

Breast Cancer - Ulcerating

Breast Cancer with Bladder Metastases

Breast Cancer with Bone Metastases

Breast Cancer with Bone and Lung Metastases

Breast Cancer with Brain Metastases

Breast Cancer with Brain and Liver Metastases

Breast Cancer with Central Nervous System Metastases

Breast Cancer with Liver Metastases

Breast Cancer with Lung Metastases

Breast Cancer with Lymphangitic Metastasis

Breast Cancer with Lymphatic Metastases

Breast Cancer with Lymph Node Metastases

Breast Cancer with Meningeal Metastases

Breast Cancer with Pericardial Effusion

Breast Cancer with Pleura Metastases

Breast Cancer with Pleural Effusion

Diedst Cancer with Fledral Effusion

Breast Cancer with Skin Metastases

Breast Cancer with Spine Metastases

Breast Cancer with Stomach Metastases

Breast Cancer - Breast Reconstruction

Breast Cancer - Comedo Type Breast Cancer

Breast Cancer - Early Stage Breast Cancer

Breast Cancer - Estrogen-Negative Breast Cancer

Breast Cancer - Inflammatory Breast Cancer

Breast Cancer - Invasive Breast Cancer

Breast Cancer - Lobular Breast Cancer

Breast Cancer - Medullary Breast Cancer

Breast Cancer - Metachronous Bilateral

Breast Cancer - Microinvasive Breast Cancer

Breast Cancer - Mucinous Breast Cancer

Breast Cancer - Node-Negative Breast Cancer

Breast Cancer - Node-Positive Breast Cancer

Breast Cancer - Occult Breast Cancer with Lymphatic Metastasis

Breast Cancer - Paget's Disease of the Nipple

Breast Cancer - Papillary Breast Cancer

Breast Cancer - Recurrent Breast Cancer

Breast Cancer - Sarcoma of the Breast

Breast Cancer - Squamous Cell Breast Cancer

Breast Cancer - Synchronous Bilateral Breast Cancer

Breast Cancer - Tubular Breast Cancer

Breast Cancer - Ulcerating Breast Cancer

Bronchial Cancer Bronchioalveolar Lung Cancer Buttock Cancer -C-

Cancer of Unknown Primary Site (CUPS)

Carcinoma of Unknown Primary

Carcinoid of the Appendix

Carcinoid of the Colon

Carcinoid of the Pancreas

Carcinoid of the Rectum

Carcinoid of the Stomach

Carcinoid Syndrome

Carcinoid Tumor

Carcinosarcoma of the Ovary

Carcinosarcoma of the Uterus

Carney's Triad

**Cavernous Sinus Cancer** 

Cecum Cancer

Central Nervous System Lymphoma

# **Central Nervous System Cancers:**

Central Nervous System Cancers - Medulloblastoma

Central Nervous System Cancers - Astrocytomas

Central Nervous System Cancers - Gliomas - Optic, Chiasmal, and Hypothalamic

Central Nervous System Cancers - Cystic Cerebellar Astrocytomas

Central Nervous System Cancers - Diffuse, Fibrillary Astrocytomas - e.g., World Health

Organization (WHO) Grade II

Central Nervous System Cancers - Astrocytoma, e.g., WHO grade III Anaplastic

Astrocytoma, and WHO grade IV

Central Nervous System Cancers - Glioblastoma (GBM)

Central Nervous System Cancers - Pilocytic Astrocytoma

Central Nervous System Cancers - Pleomorphic Xanthoastrocytoma

Central Nervous System Cancers - Subependymal Giant Cell Astrocytomas

Central Nervous System Cancers - Oligodendroglioma- Anaplastic, differentiated

Central Nervous System Cancers - Oligoastrocytoma- Anaplastic, differentiated

Central Nervous System Cancers - Ependymoma- Ellular, Papillary, Clear Cell, Tanycytic, Myxopapillary

Central Nervous System Cancers - Choroid Plexus Tumor

Central Nervous System Cancers - Meningioma- Atypical and Malignant, Parasagittal,

Falx, Olfactory Groove, Tuberculum Sellae, Sphenoid

Ridge, Cerebellopontine Angle

Central Nervous System Cancers - Schwannoma

Central Nervous System Cancers - Neurofibromas

Central Nervous System Cancers - Hemangioblastomas

Central Nervous System Cancers - Atypical Teratoid/Rhabdoid Tumors

Central Nervous System Cancers - Gorlin's, Turcot, and Li-Fraumeni syndromes

Central Nervous System Cancers - Supratentorial Parenchymal tumors

Central Nervous System Cancers - Medulloepithelioma

Central Nervous System Cancers - Neuroblastoma

Central Nervous System Cancers - Ependymoblastoma

Central Nervous System Cancers - Pineoblastoma

Central Nervous System Cancers - Pineal Parenchymal Tumors

Central Nervous System Cancers - Germinomas

Central Nervous System Cancers - Pituitary Adenoma

Central Nervous System Cancers - Craniopharyngioma

Central Nervous System Cancers - Acoustic Neuromas (Vestibular Schwannomas)

Central Nervous System Cancers - Glomus Jugulare tumors (Paragangliomas)

Central Nervous System Cancers - Chordoma and Chondrosarcoma

Central Nervous System Cancers - Hemangioblastomas

Central Nervous System Cancers - Choroid Plexus Papilloma and Carcinoma

Central Nervous System Cancers - Spinal Axis Tumors

# Centrocytic Lymphoma Cerebral Astrocytoma

## Cervix Cancer (Cervical Cancer):

# Cervix Cancer (Cervical Cancer), Adenocarcinoma In Situ:

Cervical Cancer, Adenocarcinoma In Situ - Adenoid Basal Carcinoma

Cervical Cancer, Adenocarcinoma In Situ - Adenoma Malignum

Cervical Cancer, Adenocarcinoma In Situ - Adenosquamous Carcinoma

Cervical Cancer, Adenocarcinoma In Situ - Glassy Cell Carcinoma

Cervical Cancer, Adenocarcinoma In Situ - Papillary Serous Carcinoma

# Cervix Cancer (Cervical Cancer), Anaplastic Small Cell Carcinoma

Cervix Cancer (Cervical Cancer), Cervical Intraepithelial Neoplasia

Cervix Cancer (Cervical Cancer), Malignant Mixed Müllerian Tumors

# Squamous Cell Carcinoma:

Squamous Cell Carcinoma - Large Cell Keratinizing

Squamous Cell Carcinoma - Large Call Nonkeratinizing

Squamous Cell Carcinoma - Papillary

Squamous Cell Carcinoma - Sarcomatoid Squamous Carcinoma

Squamous Cell Carcinoma - Small Cell Carcinoma

Squamous Cell Carcinoma - Verrucous Carcinoma

# **Chest Tumors (Mediastinum Tumors)**

Chiasmal Glioma

**Childhood Cancers** 

Chondroma, Intracranial

Chordoma

#### Chondrosarcoma:

Chondrosarcoma - Central

Chondrosarcoma - Clear Cell

Chondrosarcoma - Differentiated

Chondrosarcoma - Mesenchymal

# Chondrosarcoma - Peripheral

#### Chorioadenoma Destruens

#### Choriocarcinoma:

Choriocarcinoma, Syncytiotrophoblast Choriocarcinoma, Cytotrophoblast

### Choroid Plexus Carcinoma

Choroidal Melanoma

Chronic Leukemia

Chronic Lymphocytic Leukemia (CLL)

Chronic Myelogenous Leukemia (CML)

Clear Cell Ovarian Cancer

Clear Cell Sarcoma

CNS Lymphoma

## **Colon Cancer Including:**

Colon Cancer - Amine Precursor Uptake and Decarboxylation Tumor

Colon Cancer - Cecum

Colon Cancer - Lymphoma

Colon Cancer - Lymphoma - B-Cell

Colon Cancer - Lymphoma - T-Cell

Colon Cancer - Hamartomatous Polyposis Syndrome

Colon Cancer - Hereditary Nonpolyposis Colorectal Cancer

Colon Cancer - Mucinous

Colon Cancer, Neuroendocrine Carcinoma:

Colon Cancer - Neuroendocrine Carcinoma - Extrapulmonary Small Cell

Colon Cancer - Neuroendocrine Carcinoma - High-grade

Colon Cancer - Neuroendocrine Carcinoma - Oat Cell

Colon Cancer - Neuroendocrine Carcinoma - Well-differentiated Carcinoid

Colon Cancer - Recurrent

Colon Cancer - Stage A

Colon Cancer - Stage B

Colon Cancer - Stage C

Colon Cancer - Stage D

Colon Cancer - Stage I (Dukes' A)

Colon Cancer - Stage II (Dukes' B)

Colon Cancer - Stage III (Dukes' C)

Colon Cancer - Stage IV

Colon Cancer with Bone Metastases

Colon Cancer with Brain Metastases

Colon Cancer with Buttocks Metastases

Colon Cancer with Liver Metastases

Colon Cancer with Liver and Lung Metastases

Colon Cancer with Lung Metastases

WO 2007/053573 PCT/US2006/042367

18

Colon Cancer with Ovarian Metastases

Colon Cancer with Skin Metastases

Colon Cancer - Adenocarcinoma of the Colon - Mucinous (Colloid)

Colon Cancer - Adenocarcinoma of the Colon - Signet Ring

Colon Cancer - Adenomatous Polyps

Colon Cancer - Polyps

Colorectal Cancer, <u>Colon Cancer</u> Craniopharyngioma Cutaneous T-Cell Lymphoma WO 2007/053573 PCT/US2006/042367

19

-D-

DCIS - Ductal Carcinoma In Situ Dermatofibrosarcoma Protuberans Desmoid Tumor Desmoplastic Tumor Diffuse Lymphoma Diffuse, Large-Cell Lymphoma Ductal Carcinoma in Situ (DCIS) Duodenal Cancer Dysgerminoma

-E-

## Early Stage Prostate Cancer Endochodroma

## **Endocrine Cancer:**

Endocrine Cancer - Multiple Endocrine Neoplasia Type 1 (MEN 1)

Endocrine Cancer - Multiple Endocrine Neoplasia Type 2 (MEN 2)

Endocrine Cancer - MEN 2A

Endocrine Cancer - MEN 2B

Endocrine Cancer - Familial Non-MEN MTC (FMTC)

Endocrine Cancer - Sporadic MTC

Endocrine Cancer - Sporadic Thyroid Neoplasms

Endocrine Cancer - Papillary Thyroid Carcinoma

Endocrine Cancer - Follicular Adenomas

### **Endometrial Cancer:**

Endometrial Cancer - Adenosarcoma

Endometrial Cancer - Epithelial Tumors

Endometrial Cancer - Epithelial Tumors - Clear Cell

Endometrial Cancer - Epithelial Tumors - Endometrioid

Endometrial Cancer - Epithelial Tumors - Mucinous

Endometrial Cancer - Epithelial Tumors - Papillary Endometrioid

Endometrial Cancer - Epithelial Tumors - Papillary Serous

Endometrial Cancer - Epithelial Tumors - Malignant Mixed Müllerian

Endometrial Cancer - Mesenchymal Tumors:

Endometrial Cancer - Mesenchymal Tumors - Endometrial Stromal Sarcoma

Endometrial Cancer - Mesenchymal Tumors - Leiomyosarcoma

## **Ependymoma**

# Esophagus Cancer (Esophageal Cancer), Including:

Esophagus Cancer (Esophageal Cancer) - Adenoid Cystic Carcinoma

Esophagus Cancer (Esophageal Cancer) - Mucoepidermoid Carcinoma

### **Esophagus Cancer of the Gastroesophageal Junction**

Esthesioneuroblastoma

Ewing's Sarcoma

**Extensive Stage Small Cell Lung Cancer** 

**Extrahepatic Bile Duct Cancer** 

Extraskeletal Chondrosarcoma

Extraskeletal Ewing's Sarcoma

Extraskeletal Osteosarcoma

Eye Metastases

**Eye Cancer** 

Eye Cancer, Lymphoma

-F-

# Fallopian Tube Cancer Including:

Fallopian Tube Cancer - Adenocarcinomas Fallopian Tube Cancer - Eiomyosarcomas

Fallopian Tube Cancer - Transitional cell carcinomas

Fallopian Tube Cancer - Stage I Fallopian Tube Cancer - Stage II

Fallopian Tube Cancer - Stage III Fallopian Tube Cancer - Stage IV

Fallopian Tube Cancer - Carcinoma

Fallopian Tube Cancer - Ovarian Cancer

Familial Adenomatous Polyposis

Fibrosarcoma - See <u>Soft Tissue Sarcomas</u>

Fibrous Histiocytoma Follicular Lymphoma

Follicular, Small-Cleaved Cell Lymphoma

-G-

# Gardner's Syndrome

# Gallbladder Cancer, Including:

Gallbladder Cancer - Adenocarcinoma

Gallbladder Cancer - Mucinous Adenocarcinoma

Gallbladder Cancer - Papillary Adenocarcinoma

Gallbladder Cancer - Sarcoma

Gallbladder Cancer - Squamous Cell Carcinoma

#### **Gastric Cancer**

Gastrinoma

# Gastro-Esophageal (GE Junction) Cancer

**Gastrointestinal Lymphoma** 

# Gastrointestinal Stromal Tumors (GST):

Gastrointestinal Stromal Tumors - Autonomic Nerve Tumor

Gastrointestinal Stromal Tumors - Leiomyoblastoma

Gastrointestinal Stromal Tumors - Leiomyosarcoma

Gastrointestinal Stromal Tumors - Pacemaker Call Tumor

Gastrointestinal Stromal Tumors - Plexosarcoma

#### Neurofibrosarcoma

## **GE Junction Esophageal Cancer**

#### Germ Cell Tumor:

Germ Cell Tumor - Retroperitoneal Tumor

Germ Cell Tumor - Mediastinum Tumor

Germ Cell Tumor - Undescended Testicular Cancer

## **Gestational Trophoblastic Disease**

**Giant Cell Bone Tumor** 

Glioblastoma

Glioma

Gliomatosis

Gonadal Mesothelioma

Gorlin's Syndrome (Nevoid Basal Cell Carcinoma Syndrome)

Granular Lymphocytic Lymphoma

Granulocytic Leukemia

Granulosa Cell Ovarian Cancer

WO 2007/053573 PCT/US2006/042367

23

-H-

Hairy Cell Leukemia
Head and Neck Cancer
Head and Neck Cancer, Adenoid Cystic
Head and Neck Cancer, Squamous Cell
Hemangioendothelioma
Hemangiopericytoma
Hepatocelluar Carcinoma
High-Grade Lymphoma
High-Risk Breast Cancer
Histiocytoma, Malignant
Hodgkin's Disease
Hodgkin's Disease in Pregnancy
Hormone-Refractory Prostate Cancer

WO 2007/053573

24

-]-

In Situ Breast Cancer Insulinoma Intermediate-Grade Lymphoma Intraocular Melanoma Invasive Lobular Breast Cancer Islet Cell Pancreatic Cancer

-J-

# Kaposi's Sarcoma

# Kidney Cancer (Renal Cell Carcinoma), Including:

Kidney Cancer (Renal Cell Carcinoma) - Birt-Hogg-Dubé (BHD)

Kidney Cancer (Renal Cell Carcinoma) - Chromophobe Renal Carcinoma

Kidney Cancer (Renal Cell Carcinoma) - Clear Cell Renal Carcinoma

Kidney Cancer (Renal Cell Carcinoma) - Hereditary Papillary Renal Cell Carcinoma (HPRC)

Kidney Cancer (Renal Cell Carcinoma) - Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC)

Kidney Cancer (Renal Cell Carcinoma) - Onocytoma Renal Carcinoma

Kidney Cancer (Renal Cell Carcinoma) - Papillary Renal Carcinoma

Kidney Cancer (Renal Cell Carcinoma) - Papillary Renal Carcinoma, Type 1

Kidney Cancer (Renal Cell Carcinoma) - Papillary Renal Carcinoma, Type 2

Kidney Cancer (Renal Cell Carcinoma) - Von Hippel-Lindau (VHL) Clear Cell Renal Cell Carcinoma

# **Kidney Cancer with Lung Metastases Krukenberg Tumor**

-L-

Large-Cell Lung Cancer Large-Cell Lymphoma Large-Cell, Diffuse Lymphoma Larynx Cancer (Laryngeal Cancer) Leiomyosarcoma:

Leiomyosarcoma - Foot

Leiomyosarcoma - Pulmonary Artery

Leiomyosarcoma - Vena Cava

Leiomyosarcoma - Uterus

# Lentigo Maligna

#### Leukemia:

Leukemia - Acute

Leukemia - Acute Lymphocytic (ALL)

Leukemia - Acute Megakaryoblastic leukemia

Leukemia - Acute Monocytic (AML)

Leukemia - Acute Myelogenous (AML)

Leukemia - Acute Myeloid (AML)

Leukemia - Acute Promyelocytic (APL)

Leukemia - Chronic

Leukemia - B-Cell Chronic Lymphocytic Leukemia

Leukemia - Chronic granulocytic leukemia

Leukemia - Chronic Lymphocytic (CLL)

Leukemia - Chronic Myelogenous

Leukemia - Chronic Myeloid (CML)

Leukemia - Chronic Myelomonocytic (CMML)

Leukemia - CML, Philadelphia-Negative

Leukemia - CMML

Leukemia - Cutis

Leukemia - Granulocytic

Leukemia - Granulocytic Sarcomas and Chloromas (Leukemic tumors)

Leukemia - Hairy Cell

Leukemia - Infant Acute Megakaryoblastic Leukemia

Leukemia - Large Granular Lymphocyte Leukemia

Leukemia - Lymphoblastic

Leukemia - Mature B-Cell Acute Lymphocytic Leukemia

Leukemia - Precursor B-Lymphoblastic Leukemia

Leukemia - Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Leukemia - Prolymphocytic

Leukemia - Promyelocytic

Leukemia - Secondary Myeloid Leukemia

Leukemia - T-Cel

### Li-Fraumeni syndrome

### Linitis Plastica

Limited Stage Small Cell Lung Cancer

# Lip Cancer Liposarcoma

# Liver Cancer Including:

Liver Cancer - Angiosarcoma

Liver Cancer - Cholangiocarcinoma (Bile Duct Cancer):

Liver Cancer - Cholangiocarcinoma (Bile Duct Cancer) - Distal

Liver Cancer - Cholangiocarcinoma (Bile Duct Cancer) - Hilar (Klatskin's Tumors)

Liver Cancer - Cholangiocarcinoma (Bile Duct Cancer) - Intrahepatic

Liver Cancer - Cholangiocellular Carcinoma

Liver Cancer - Emangioendotheliomas

Liver Cancer - Epithelioid Hemangioendothelioma

Liver Cancer - Fibrosarcoma

Liver Cancer - Leiomyosarcoma

Liver Cancer - Hemangioendothelioma

Liver Cancer - Hemangiosarcoma

Liver Cancer - Hepatic Cystadenocarcinoma

Liver Cancer - Hepatoblastoma

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma):

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Carcinosarcoma

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Childhood

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Clear Cell

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Combined

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) -

#### Fibrolamellar

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Giant Cell

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Sclerosing, Hepatoblastoma

Liver Cancer - Hepatocellular Carcinoma (Liver Cell Carcinoma) - Spindle Cell

Liver Cancer - Histiocytoma

Liver Cancer - Lymphoma

Liver Cancer - Malignant Fibrous

Liver Cancer - Malignant Schwannoma

Liver Cancer - Mesenchymal sarcoma

Liver Cancer - Metastases

Liver Cancer - Mixed Hepatocellular Cholangiocarcinoma

Liver Cancer - Osteosacoma

Liver Cancer - Rhabdomyosarcoma

Liver Cancer - Stage I

Liver Cancer - Stage II

Liver Cancer - Stage III

Liver Cancer - Stage IV

Liver Cancer - Recurrent Liver Cancer

Liver Cancer - Undifferentiated Liver Cancer

```
Lobular Carcinoma in Situ (LCIS)
Lobular Hyperplasia
Low-Grade Lymphoma
Lung Cancer:
```

Lung Cancer - Adenocarcinoma

Lung Cancer - Bronchioalveolar

Lung Cancer - Cystic Mucinous

Lung Cancer - Extrapulmonary Small Cell Anaplastic Carcinoma - Limited

Lung Cancer - Extrapulmonary Small Cell Anaplastic Carcinoma - Extensive

Lung Cancer - Germ Cell

Lung Cancer - Giant Cell

Lung Cancer - Large-Cell

Lung Cancer - Mucinous

Lung Cancer - Non-Small Cell Lung Cancer - Including:

Lung Cancer - Non-Small Cell Lung Cancer - (NSCLC)

Lung Cancer - Non-Small Cell Lung Cancer with Bone Metastases

Lung Cancer - Non-Small Cell Lung Cancer with Brain Metastases

Lung Cancer - Non-Small Cell Lung Cancer with Liver Metastases

Lung Cancer - Non-Small Cell Lung Cancer with Lymph Node Metastases

Lung Cancer - Non-Small Cell Lung Cancer with Skin Metastases

Lung Cancer - Non-Small Cell Lung Cancer - Stage I

Lung Cancer - Non-Small Cell Lung Cancer - Stage IIA

Lung Cancer - Non-Small Cell Lung Cancer - Stage IIB

Lung Cancer - Non-Small Cell Lung Cancer - Stage IIIA

Lung Cancer - Non-Small Cell Lung Cancer - Stage IIIB

Lung Cancer - Non-Small Cell Lung Cancer - Stage IV

Lung Cancer - Non-Small Cell Lung Cancer - Recurrent

Lung Cancer - Adenocarcinomas:

Lung Cancer - Adenocarcinomas - Acinar

Lung Cancer - Adenocarcinomas, Bronchioloalveolar Carcinoma

Lung Cancer - Adenocarcinomas, Bronchioloalveolar Carcinoma,

Nonmucinous (Clara Cell/type II Pneumocyte Type)

Lung Cancer - Adenocarcinomas, Bronchioloalveolar Carcinoma, Mixed Mucinous and Nonmucinous/Indeterminate cell type

Lung Cancer - Adenocarcinomas, Bronchioloalveolar Carcinoma, Mucinous (Goblet Cell) type

Lung Cancer - Adenocarcinomas - Clear Cell Adenocarcinoma

Lung Cancer - Adenocarcinomas - Mucinous (Colloid) Adenocarcinoma

Lung Cancer - Adenocarcinomas - Mucinous Cystadenocarcinoma

Lung Cancer - Adenocarcinomas - Papillary

Lung Cancer - Adenocarcinomas - Signet-Ring Adenocarcinoma

Adenocarcinomas - Solid Adenocarcinoma with Mucin Formation

Lung Cancer - Adenocarcinomas - Well-differentiated Fetal Adenocarcinoma

Adenosquamous Carcinoma

Atypical Adenomatous Hyperplasia

Carcinoid Tumors, Atypical

Carcinoid Tumors, Typical

Carcinosarcoma

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

**Epidermoid Carcinoma** 

Giant Cell Carcinoma

## Large Cell Carcinoma:

Large Cell Carcinoma - Basaloid Carcinoma

Large Cell Carcinoma - Clear Cell Carcinoma

Large Cell Carcinoma - Combined Large Cell Neuroendocrine Carcinoma

Large Cell Carcinoma - Large Cell Carcinoma with Rhabdoid Phenotype

Large Cell Carcinoma - Large Cell Neuroendocrine Carcinoma

Large Cell Carcinoma - Lymphoepithelioma-like Carcinoma

### Pleomorphic Carcinoma

**Pulmonary Blastoma** 

Spindle Cell Carcinoma

## Squamous Cell Carcinomas:

Squamous Cell Carcinomas - Basaloid

Squamous Cell Carcinomas - Clear Cell

Squamous Cell Carcinomas - Papillary

Squamous Cell Carcinomas - Small Cell

# Lung Cancer, Squamous Dysplasia/Carcinoma in situ

Lung Cancer, Superior Sulcus Tumors (Pancoast tumors)

Lung Cancer, Unclassified

### Lung Cancer, Recurrent

# Lung Cancer, Small Cell:

Lung Cancer - Small Cell - Combined small cell carcinoma

Lung Cancer - Small Cell - Mixed small cell/large cell carcinoma

Lung Cancer - Small Cell - Pure small cell

Lung Cancer - Small Cell - Extensive Stage

Lung Cancer - Small Cell - Limited Stage

Lung Cancer - Small Cell with Brain Metastases

## Lung Cancer, Squamous

Lung Cancer, Stage I

Lung Cancer, Stage II

Lung Cancer, Stage III

Lung Cancer, Stage IIIA

Lung Cancer, Stage IIIB

Lung Cancer, Stage IV

Lung Cancer with Adrenal Gland Metastases

**Lung Cancer with Bone Metastases** 

Lung Cancer with Brain Metastases

Lung Cancer with Liver Metastases

**Lung Cancer with Lymph Node Metastases** 

Lung Cancer with Ovarian Metastases

Lung Cancer with Skin Metastases

**Lung Metastases** 

Lymph Node Excision
Lymphangitic Metastasis
Lymph Node Metastases
Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Lymphocytic Lymphoma
Lymphoma:

Lymphoma - Lymphoblastic Lymphoma

Lymphoma - Lymphocytic Lymphoma

Lymphoma - Lymphocytic, Large Granular

Lymphoma - Lymphocytic, Small

Lymphoma - AIDS Related

Lymphoma - Anaplastic

Lymphoma - Anaplastic Large Cell (ALCL)

Lymphoma - Breast

Lymphoma - B-Cell

Lymphoma - B-Cell Large-Lymphomatoid Granulomatosis Type

Lymphoma - B-Cell Large Diffuse

Lymphoma - B-Cell Monocytoid

Lymphoma - Central Nervous System

Lymphoma - Cutaneous T-Cell:

Lymphoma - Cutaneous T-Cell - Mycosis Fungoides, Agetoid Reticulosis or Woringer-Kolopp disease

Lymphoma, Granulomatous slack skin:

Lymphoma - Granulomatous slack skin - Lymphomatoid

Lymphoma - Granulomatous slack skin - Papulosis

Lymphoma - Granulomatous slack skin - Primary

Lymphoma - Granulomatous slack skin - Cutaneous

Lymphoma - CD30+ Large T-cell Lymphoma

Lymphoma - CD56+ "Nasal-Type" NK/T-Cell Lymphoma

Lymphoma - Diffuse

Lymphoma - Diffuse, Large-Cell

Lymphoma - Enteropathy-Type T-Cell Lymphoma

Lymphoma - Eye

Lymphoma - Follicular

Lymphoma - Follicular, Small-Cleaved Cell

Lymphoma - Gastrointestinal

Lymphoma - Granular, Lymphocytic

Lymphoma - Hepatosplenic T-Cell Lymphoma

Lymphoma - High-Grade

Lymphoma - Hodgkin's Disease:

Lymphoma - Hodgkin's Disease - Paragranuloma

Lymphoma - Hodgkin's Disease - Granuloma

Lymphoma - Hodgkin's Disease - Sarcoma

Lymphoma - Hodgkin's Disease - Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Lymphoma - Hodgkin's Disease - Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Lymphoma - Hodgkin's disease - Mixed-Cellularity Hodgkin's Lymphoma

Lymphoma - Hodgkin's disease - Nodular Sclerosis Hodgkin's Lymphoma

Lymphoma - Hodgkin's disease - Lymphocyte-Depleted Hodgkin's Lymphoma

Lymphoma - Hodgkin's disease - Lymphocyte-Predominant Hodgkin's

# Lymphoma

Lymphoma - Hodgkin's disease - Lymphocyte-Rich Classic Hodgkin's

## Lymphoma

Lymphoma - Intermediate Grade

Lymphoma - Hodgkin's disease, Intravascular Large B-Cell Lymphoma

Lymphoma - Large-Cell

Lymphoma - Large-Cell, Diffuse

Lymphoma - Low-Grade

Lymphoma - Hodgkin's disease, Low-Grade B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue

Lymphoma - Hodgkin's disease, Lymphoplasmacytic lymphoma

Lymphoma - MALT

Lymphoma - Mantle Cell

## Lymphoma - Non-Hodgkin's, Including:

Lymphoma - Non-Hodgkin's - High Grade

Lymphoma - Non-Hodgkin's - Intermediate Grade

Lymphoma - Non-Hodgkin's - Low Grade

Lymphoma - Non-Hodgkin's - Burkitt's & Atypical Burkitt's

Lymphoma - Non-Hodgkin's - Diffuse

Lymphoma - Non-Hodgkin's - Non-Burkitt's

Lymphoma - Non-Hodgkin's - T-Cell, Cutaneous

Lymphoma - Non-Hodgkin's - Immunoblastic Diffuse

Lymphoma - Non-Hodgkin's - Large Cell Follicular

Lymphoma - Non-Hodgkin's - Mixed Cell Diffuse

Lymphoma - Non-Hodgkin's - Small Cleaved Cell Follicular

Lymphoma - Non-Hodgkin's - Small Lymphocytic

Lymphoma - Non-Hodgkin's - Mixed Follicular

Lymphoma - Non-Hodgkin's - Small Cleaved Cell Diffuse.

Lymphoma - Non-Hodgkin's - Intermediately Differentiated Diffuse

Lymphoma - Non-Hodgkin's - Cutaneous T-cell

# Lymphoma, Orbital

Lymphoma, Peripheral T-Cell

Precursor B-Lymphoblastic Lymphoma

Lymphoma, Primary Central Nervous System

Primary Effusion Lymphoma

Primary leptomeningeal lymphoma

Primary Mediastinal (Thymic) Large B-Cell LymphomaPrimary spinal cord

lymphoma

Richter's lymphoma

Lymphoma, Small Cleaved Cell
Lymphoma, Soft tissue
Splenic Marginal Zone Lymphoma with or without Villous Lymphocytes
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
T-Cell-Rich/Histiocyte-Rich Large B-Cell Lymphoma
Lymphoma, Thyroid

-M-

**Malignant Ascites** 

Malignant Carcinoid Syndrome:

Malignant Carcinoid Syndrome - Atypical Malignant Carcinoid Syndrome - Typical

Malignant Hemangiopericytoma

Malignant Fibrous Histiocytoma

Malignant Peripheral Nerve Sheath Tumor

**Malignant Pleural Effusion** 

Malignant Pleural Mesothelioma

Malignant Schwannoma

MALT Lymphoma

Mantle Cell Lymphoma

Mediastinal Neoplasms, including:

Mediastinal Neoplasms - Chemodectoma (Paraganglioma)

Mediastinal Neoplasms - Choriocarcinoma

Mediastinal Neoplasms - Endodermal Sinus Tumors (Yolk Sac Tumors)

Mediastinal Neoplasms - Fibroelastoma

Mediastinal Neoplasms - Fibroma

Mediastinal Neoplasms - Fibrosarcoma

Mediastinal Neoplasms - Ganglioneuroblastoma

Mediastinal Neoplasms - Ganglioneuroma

Mediastinal Neoplasms - Granular Cell Myoblastomas

Mediastinal Neoplasms - Hemangioendothelioma

Mediastinal Neoplasms - Hemangioma

Mediastinal Neoplasms, Histiocytic Lymphoma

Mediastinal Neoplasms, Immature Teratomas

Mediastinal Neoplasms, Leiomyoma

Mediastinal Neoplasms, Leiomyosarcoma

Mediastinal Neoplasms, Lipoma

Mediastinal Neoplasms, Liposarcoma

Mediastinal Neoplasms, Lymphangioma

Mediastinal Neoplasms, Lymphangiomyoma

Mediastinal Neoplasms, Malignant Fibrous Histiocytoma

Mediastinal Neoplasms, Mesenchymoma

Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma,

Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Endodermal Sinus Elements

Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Seminomatous Elements

Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Tetroid

Elements

Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Trophoblastic Elements

Mediastinal Neoplasms, Myxoma

Mediastinal Neoplasms, Neuroblastoma

Mediastinal Neoplasms, Neurofibroma

Mediastinal Neoplasms, Neuroilemoma (schwannoma)

Mediastinal Neoplasms, Neurosarcoma

Mediastinal Neoplasms, Nonseminomatous

Mediastinal Neoplasms, Permeative Neuroectodermal Tumor

Mediastinal Neoplasms, Pheochromocytoma

Mediastinal Neoplasms, Pure Embryonal Cell Carcinoma

Mediastinal Neoplasms, Rhabdomyosarcoma

Mediastinal Neoplasms, Seminoma

Mediastinal Neoplasms, Xanthogranuloma

## Medulary Thyroid Carcinoma Medulloblastoma

### Melanomas including:

Melanomas, Amelanotic melanoma

Melanomas, Cutaneous

Melanomas, Intraocular

Melanomas, Uveal-spindle cell (A, B, or both), mixed cell, epithelioid cell

Melanomas, Soft Tissue

Melanomas, Extraocular Extension

Melanomas, Multiple Choroidal Malignant Melanoma

Melanomas, with Brain Metastases

Melanomas, with Liver Metastases

Melanomas, with Lung Metastases

Melanomas, Melanoma-associated retinopathy

Meningeal Cancer Meningeal Metastases Meningioma Merkel Cell Carcinoma Merkel Cell Skin Cancer

#### Mesothelioma:

Mesothelioma, Biphasic

Mesothelioma, Epithelial

Mesothelioma, Poorly Differentiated

Mesothelioma, Sarcomatoid

### Mesenchymal Chondrosarcoma

# Metastatic carcinoma of unknown primary site:

Metastatic carcinoma of unknown primary site, poorly differentiated neoplasm Metastatic carcinoma of unknown primary site, poorly differentiated carcinoma (with or without features of adenocarcinoma

Metastatic carcinoma of unknown primary site, well-differentiated and moderately well-differentiated adenocarcinoma

Metastatic carcinoma of unknown primary site, Metastatic gestational Choriocarcinoma

Metastatic Melanoma
Mixed Mullerian Tumor
Mucinous Carcinoma
Multiple Myeloma
Muscle-Invasive Bladder Tumor
Mycosis Fungoides
Myeloblastomas (chloromas or granulocytic sarcomas)
Myelodysplasia
Myelodysplastic Syndrome
Myeloma, Bence-Jones
Myeloproliferative Disorder

# Myelodysplastic syndromes (MDS):

Myelodysplastic syndromes (MDS), refractory anemia (RA),

Myelodysplastic syndromes (MDS), preleukemia, or smoldering leukemia

Myelodysplastic syndromes (MDS), hypocellular MDS

Myelodysplastic syndromes (MDS), with extensive fibrosis

Myelodysplastic syndromes (MDS), unclassifiable MDS

Myelodysplastic syndromes (MDS), 5q- syndrome

Myelodysplastic syndromes (MDS), with Myelofibrosis

Myelodysplastic Syndromes (MDS), hypoplastic

Myelodysplastic Syndromes (MDS), with Eosinophilia or Basophilia

-N-

Nail/Nail Bed Cancer Nasal Cavity Cancer Nasopharynx Cancer Neck, Radical Dissection Neoplastic Meningitis Nerve Sheath Tumors Neuroblastoma (Adult) Neuroblastoma (Child)

#### **Neuroendocrine Tumors:**

Neuroendocrine Tumors, Carcinoids (Foregut, Hindgut, Midgut)

Neuroendocrine Tumors, Glandular

Neuroendocrine Tumors, Insular

Neuroendocrine Tumors, Mixed

Neuroendocrine Tumors, Trabecular

Neuroendocrine Tumors, Undifferentiated

Neurofibromatosis Type I (Von Reckling-Hausen's Disease) Neurologic Paraneoplastic Syndrome

Nose Tumor

-O-

Ocular Melanoma
Olfactory Cancer
Oligodendroglioma
Optic Glioma
Oral Cancer
Orbital Lymphoma
Oropharynx Cancer
Osteochondroma
Osteogenic Sarcoma
Osteoid Tumors

#### Osteosarcoma:

Osteosarcoma, Central Medullary Osteosarcoma, Low-Grade Intraosseous Osteosarcoma, Paget's Sarcoma Osteosarcoma, Parosteal Osteosarcoma, Periosteal Osteosarcoma, Small Cell

Ovarian Cancer (Adult) Ovarian Cancer (Child) Ovarian Cancer, Advanced

# Ovarian Cancer, Androblastoma:

Ovarian Cancer, Androblastoma, Gynandroblastoma

Ovarian Cancer, Androblastoma, Hilus Cell Tumor

Ovarian Cancer, Androblastoma, Sertolid Cell Tumor (Tubular Adenoma of Pick)

Ovarian Cancer, Androblastoma, Sertoli-Leydig Cell Tumor

Ovarian Cancer, Androblastoma, Leydig Cell Tumor

Ovarian Cancer, Androblastoma, Tubular Androblastoma

Ovarian Cancer, Androblastoma, Unclassified

## Ovarian Cancer, Borderline:

Ovarian Cancer, Borderline, Endometrioid

Ovarian Cancer, Borderline, Mucinous,

Ovarian Cancer, Borderline, Mucinous, Micropapillary Serous Carcinoma Ovarian Cancer, Borderline, Mucinous, Pseudomyxoma Peritonei Serous

#### Ovarian Cancer, Carcinosarcoma

#### Ovarian Cancer, Endometrioid Tumor:

Ovarian Cancer, Endometrioid Tumor, Brenner Tumor

Ovarian Cancer, Endometrioid Tumor, Carcinoma

Ovarian Cancer, Endometrioid Tumor, Carcinoma, Adenoacanthoma

Ovarian Cancer, Endometrioid Tumor, Carcinoma, Adenocarcinoma

Ovarian Cancer, Endometrioid Tumor, Carcinoma, Malignant Adenofibroma,

Ovarian Cancer, Endometrioid Tumor, Carcinoma, Malignant Adenofibroma,

Ovarian Cancer, Endometrioid Tumor, Carcinoma, Cystadenofibroma

Ovarian Cancer, Endometrioid Tumor, Clear Cell (mesonephroid) Tumor,

Ovarian Cancer, Endometrioid Tumor, Clear Cell (mesonephroid) Tumor, Adenocarcinoma

Ovarian Cancer, Endometrioid Tumor, Clear Cell (mesonephroid) Tumor, Carcinoma

Ovarian Cancer, Endometrioid Tumor, Endometrioid Stromal Sarcoma

Ovarian Cancer, Endometrioid Tumor, Mesodermal (Mullerian) Mixed Tumor,

Ovarian Cancer, Endometrioid Tumor, Mesodermal (Mullerian) Mixed Tumor, Heterologous

Ovarian Cancer, Endometrioid Tumor, Mesodermal (Mullerian) Mixed Tumor, Homologous

Ovarian Cancer, Endometrioid Tumor, Mixed Epithelial Tumor

Ovarian Cancer, Endometrioid Tumor, Unclassified

Ovarian Cancer, Endometrioid Tumor, Undifferentiated Carcinoma

## Ovarian Cancer, Epithelial

#### Ovarian Cancer, Germ Cell:

Ovarian Cancer, Germ Cell, Dysgerminoma

Ovarian Cancer, Germ Cell, Embryonal Carcinoma

Ovarian Cancer, Germ Cell, Endodermal Sinus Tumor

Ovarian Cancer, Germ Cell, Polyembryoma

#### Ovarian Cancer, Gonadoblastoma:

Ovarian Cancer, Gonadoblastoma, Mixed Ovarian Cancer, Gonadoblastoma, Pure

,

#### Ovarian Cancer, Granulosa-Stromal Cell Tumor:

Ovarian Cancer, Granulosa-Stromal Cell Tumor, Fibroma
Ovarian Cancer, Granulosa-Stromal Cell Tumor, Granulosa Cell Tumor
Ovarian Cancer, Granulosa-Stromal Cell Tumor, Thecoma-Fibroma Tumor
Ovarian Cancer, Granulosa-Stromal Cell Tumor, Unclassified

# Ovarian Cancer, Lipoid Cell Tumor:

Ovarian Cancer, Lipoid Cell Tumor, Choriocarcinoma Ovarian Cancer, Lipoid Cell Tumor, Mixed

Ovarian Cancer, Lipoid Cell Tumor, Teratoma.

Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Carcinoid

Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Immature

Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Mature Dermoid Cyst with Malignant Transformation

Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Monodermal

Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Struma Ovarii

Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Struma Ovarii and Carcinoid

# Ovarian Cancer, Malignant Mucinous Tumor:

Ovarian Cancer, Malignant Mucinous Tumor, Adenocarcinoma Ovarian Cancer, Malignant Mucinous Tumor, Adenocarcinoma Cystadenocarcinoma

Ovarian Cancer, Malignant Mucinous Tumor, Malignant Adenofibroma
Ovarian Cancer, Malignant Mucinous Tumor, Malignant Adenofibroma
Cystadenofibroma

#### Ovarian Cancer, Malignant Serous Tumor:

Ovarian Cancer, Malignant Serous Tumor, Adenocarcinoma,
Ovarian Cancer, Malignant Serous Tumor, Adenocarcinoma, Papillary
Adenocarcinoma
Ovarian Cancer, Malignant Serous Tumor, Adenocarcinoma, Papillary
Cystadenocarcinoma

Ovarian Cancer, Malignant Serous Tumor, Malignant Adenofibroma, Ovarian Cancer, Malignant Serous Tumor, Malignant Adenofibroma, Cystadenofibroma

Ovarian Cancer, Malignant Serous Tumor, Surface Papillary Carcinoma

Ovarian Cancer, Peritoneal Ovarian Cancer, Recurrent Ovarian Cancer, Sarcoma Ovarian Cancer, Stage I Ovarian Cancer, Stage II
Ovarian Cancer, Stage III
Ovarian Cancer, Stage IV
Ovarian Cancer, Stromal Cell
Ovarian Cancer with Bone Metastases
Ovarian Cancer with Liver Metastases
Ovarian Cancer with Lung Metastases
Ovarian Cancer with Meningeal Metastases
Ovarian Cancer with Pleural Effusion
Ovarian Cancer with Spleen Metastases

-P-

# Paget's Disease of the Breast

# Pancreatic Cancer including:

Pancreatic Cancer, Acinar cell carcinoma

Pancreatic Cancer, Adenocarcinoma:

Pancreatic Cancer - Adenocarcinoma, Anaplastic

Pancreatic Cancer - Adenocarcinoma, Adenosquamous

Pancreatic Cancer - Adenocarcinoma, Colloid Ductal (mucinous noncystics)

Pancreatic Cancer - Adenocarcinoma, Ductal Adenocarcinoma

Pancreatic Cancer - Adenocarcinoma, Medullary

Pancreatic Cancer - Adenocarcinoma, Signet-ring Cell

Pancreatic Cancer - Adenocarcinoma, Undifferentiated carcinoma with

osteoclast-like giant cells

Pancreatic Cancer- Carcinoid

Pancreatic Cancer, Cystic Neoplasms:

Pancreatic Cancer, Cystic Neoplasms, Intraductal Papillary Mucinous Neoplasms

Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms

Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms Borderline

Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms

Cystadenocarcinoma

Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms

Cystadenoma

Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms Mucinous Cystic Neoplasm with In Situ Carcinoma

Pancreatic Cancer, Cystic Neoplasms, Serous Cyctic Neoplasms Pancreatic Cancer, Inoperable

Pancreatic Cancer, Islet Cell

Pancreatic Cancer, Islet Cell, gastrinoma

Pancreatic Cancer, Islet Cell, insulinoma

Pancreatic Cancer, Islet Cell, lucagonoma

Pancreatic Cancer - Operable

Pancreatic Cancer - Pancreatoblastoma

Pancreatic Cancer with Liver Metastases

Pancreatic Cancer - Stage I

Pancreatic Cancer - Stage II

Pancreatic Cancer - Stage III

Pancreatic Cancer - Stage IVA

Pancreatic Cancer - Stage IVB

Pancreatic Cancer - Pancreatic endocrine tumors (PET)

Pancreatic Cancer - PPoma

Pancreatic Cancer - VIPoma

Pancreatic Cancer, Recurrent Pancreactic Cancer

Pancreatic Cancer, Islet cell tumors, gastrinoma

Pancreatic Cancer, Borderline Pancreatic Tumors

Paraganglioma
Paranasal Sinus Cancer
Paraneoplastic Syndromes

# **Ectopic Adrenocorticotropic Hormone Syndrome:**

Syndrome of Inappropriate Antidiuretic Hormone Production Protein-Losing Enteropathy Cutaneous paraneoplastic syndrom Paget's disease of the breast Pancreatic Cancer, Islet Cell

Acrokeratosis paraneoplastica

Melanosis

acanthosis nigricans

Sweet's syndrome

Necrolytic migratory erythema

Multicentric reticulohistiocytosis

Paraneoplastic pemphigus

Acquired ichthyosis

Dermatomyositis

Pachydermoperiostosis

Hypertrichosis lanuginosa acquisita (malignant down)

Muir-Torre syndrome

Subacute Sensory Neuronopathy and Encephalomyeloneuritis

Limbic Encephalitis

Acute polyradiculoneuropathy

Hypertrophic Osteoarthropathy

Dermatomyositis

Paraneoplastic Peripheral Neuropathies

Paraneoplastic Motor Neuron Disorders

Paraneoplastic Vision Loss

Neuromuscular Junction Disorders

Paraneoplastic neuromyotonia

paraneoplastic encephalomyelitis

Paraneoplastic parkinsonian syndromes

#### Parathyroid neoplasia

## Parathyroid carcinoma Parotid Gland Cancer Pelvic Tumor

#### Penis Cancer:

Penis Cancer - Advanced Penile Cancer

Penis Cancer - Balantitis Xerotica Obliterans

Penis Cancer - Buschke-Löwenstein Tumor

Penis Cancer - Carcinoma In Situ

Penis Cancer - Invasive Penile Cancer

Penis Cancer - Penile Verrucous Carcinoma

## Periampullary Cancer

#### Pericardial Effusion:

Pericardial Mesothelioma Peripheral Nerve Sheath Tumor Peripheral T-Cell Lymphoma

#### Peritoneal cancer:

Disseminated peritoneal adenomucinosis

Extraovarian Serous Carcinoma

Extraovarian Peritoneal Serous Papillary Carcinoma

Serous Surface Carcinoma of the Peritoneum

Serous Surface Papillary Carcinoma

Papillary Serous Carcinoma of the Peritoneum

Multiple Focal Peritoneal Papillary Carcinoma

Primary peritoneal carcinoma

Primary Peritoneal Mesothelioma:

Adenomatoid

localized fibrous mesothelioma

multicystic and well-differentiated papillary peritoneal mesotheliomas

epithelial

sarcomatoid

mixed (elements of both epithelial and sarcomatoid

Primary Peritoneal Papillary Serous Adenocarcinoma

Peritoneal Carcinomatosis:

mucinous adenocarcinoma of the appendix and colon adenocarcinoma of the colon, stomach, or pancreas

Pseudomyxoma Peritonei

Peutz-Jeghers syndrome Pheochromocytoma Pinealoma Pineoblastoma

## Placental-Site Trophoblastic Tumors Plasmacytoma

## Plasma Cell Neoplasms:

plasma cell myeloma
monoclonal gammopathy of unknown significance (MGUS)
astleman's disease
α-heavy-chain disease
Waldenström's macroglobulinemia (WM)
plasma cell leukemia
multiple myeloma (MM)
Solitary Plasmacytoma
Indolent MyelomaPleura Cancer

Pleura Metastases
Pleural Effusion, Malignant
Pleural Mesothelioma, Malignant
Preleukemia
Primary Central Nervous System Lymphoma
Primitive Neuroectodermal Tumor (PNET) (Adult)
Primitive Neuroectodermal Tumor (PNET) (Child)
Prolymphocytic Leukemia
Promyelocytic Leukemia
Prophylactic Mastectomy

#### **Prostate Cancer:**

Acinar Adenocarcinoma
Ductal Carcinoma

Intralobular Acinar Carcinoma Malignant Mesenchymal Tmors

> Angiosarcoma Chondrosarcoma

Liposarcoma

Myosarcoma

Osteosarcoma Rhabdomyosarcomas

Leiomyosarcomas

Mucinous Carcinoma

Proximal Ductal Epithelium Adenocarcinoma

Scirhous Patern Tumors

Transitional Cell Tumors

Prostate Cancer, Early-Stage Prostate Cancer, Hormone Refractory Prostate Cancer in the Elderly Prostate Cancer, Small Cell Prostate Cancer, Stage A (Stage I)
Prostate Cancer, Stage B (Stage II)
Prostate Cancer, Stage C (Stage III)
Prostate Cancer, Stage D (Stage IV)
Prostate Cancer, Transitional Cell
Prostate Cancer with Bone Metastases
Prostatic Intraepithelial Neoplasia (PIN)
PSA
Pseudomyxoma Peritonei

-R-

Rectal Cancer, Stage I

Rectal Cancer, Stage II

Rectal Cancer, Stage III

**Rectal Cancer with Brain Metastases** 

**Rectal Cancer with Liver Metastases** 

**Recurrent Colon Cancer** 

**Recurrent Colorectal Cancer** 

**Recurrent Lung Cancer** 

Recurrent Melanoma

**Recurrent Ovarian Cancer** 

**Recurrent Prostate Cancer** 

**Recurrent Rectal Cancer** 

Relapsed Lymphoma

Renal Cell Carcinoma

Renal Cell Carcinoma with Lung Metastases

**Renal Pelvis Cancer** 

Retinoblastoma (Adult)

Retinoblastoma (Child)

Rhabdomyosarcoma

Richter's Syndrome

Rising PSA as an Indication of Recurrent Prostate Cancer

47

-S-

## Salivary Gland Cancer including:

Adenoid cystic carcinoma Mucoepidermoid carcinoma

Sarcoma of Bone
Sarcomatoid Carcinoma
Schwannoma, Malignant
Sebaceous Carcinoma
Sezary Syndrome
Sinus, Cavernous
Sinus Cancer
Sinus Cancer, Cavernous
Sinus Cancer, Endodermal
Sinus Cancer, Esthesioneuroblastoma
Sinus Cavity Cancer

#### Skin Cancer:

Basal Cell- nodular, nevoid, superficial, morpheaform (also termed aggressive-growth BCC or infiltrative BCC), pigmented, cystic BCC, and fibroepithelioma of Pinkus (FEP)

Merkel Cell

Squamous Cell- keratoacanthoma, periungual

Skin Metastases

Atypical fibroxanthoma

Actinic keratoses

Dermatofibroma

Desmoplastic trichoepithelioma

Microcystic adrexal carcinoma

Non-melanoma skin cancer

Verrucous carcinoma

Malignant Fibrous Histiocytoma

Dermatofibrosarcoma Protuberans

Bednar Tumor

Angiosarcoma

Kaposi's Sarcoma

Carcinoma Metastatic to Skin

Small Cell Bladder Cancer Small Cell Lung Cancer Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer with Brain Metastases Small Cell Lung Cancer with Liver Metastases Small Cleaved Cell Lymphoma

# **Small Intestine Cancer, including:**

Adenocarcinoma

Carcinoid

Foregut Hindgut

Midgut

Fibromatosis (Desmoid Tumor)

Gastrointestinal Stromal Tumor

Inflammatory Fibroid Polyps

Lymphoma

Burkitt's Lymphoma

Diffuse Large B-Cell Lymphoma

Mucosal-Associated Lymphoid Tissue Lymphoma

T-Cell Lymphomas of the Small Intestine

Myofibroblastic Tumor

Schwannoma

Simple Leiomyoma

Solitary Fibrous Tumor

True Leiomyoma

## Soft Tissue Lymphoma

## **Soft Tissue Sarcoma:**

Soft Tissue Sarcoma (Adult)

Soft Tissue Sarcoma (Child)

Soft Tissue Sarcoma, Angiosarcoma

Soft Tissue Sarcoma, Clear Cell

Soft Tissue Sarcoma, Dermatofibrosarcoma Protuberans

Soft Tissue Sarcoma, Hemangiopericytoma

Soft Tissue Sarcoma, Leiomyosarcoma

Soft Tissue Sarcoma, Liposarcoma

Soft Tissue Sarcoma, Malignant Fibrous Histiocytoma

Soft Tissue Sarcoma, Primitive Neuroectodermal (Adult)

Soft Tissue Sarcoma, Primitive Neuroectodermal (Child)

Soft Tissue Sarcoma, Rhabdomyosarcoma

Soft Tissue Sarcoma, Synovial

Synovial Sarcoma

## **Epithelioid Sarcoma:**

Ewing's Sarcoma

Extraskeletal Cartilaginous Tumors

Extraskeletal Chondrosarcoma

Mesenchymal Chondrosarcoma

Myxoid Chondrosarcoma

Extraskeletal Osteosarcoma

Fibrohistiocytic Tumors

Atypical Fibroxanthoma

Angiomatoid Fibrous Histiocytoma

Dermatofibrosarcoma Protuberans

Giant Cell Fibroblastoma

Malignant Fibrous Histiocytoma

Giant Cell

Inflammatory

Myxoid

Storiform-Pleomorphic

Plexiform Fibrohistiocytic Tymor

# Fibrous Tumors

**Fibromatoses** 

Deep Fibromatoses

Abdominal Fibromatosis

Extraabdominal Fibromatosis

Intraabdominal Fibromatosis

Infantile Fibromatosis

Mesenteric Fibromatosis

Superficial Fibromatoses

Palmar

Penile (Peyronie's Fibromatosis)

## Fibrosarcoma

Adult Fibrosarcoma

Inflammatory Fibrosarcoma

Infantile Fibrosarcoma

Inflammatory Myofibroblasic Tumor

Gastrointestinal Stromal Tumors

Kaposi's Sarcoma

Lipomatous Tumors

Atypical Lipoma

Liposarcoma

Dedifferentiated Liposarcoma

Myxoid (Round Cell) Liposarcoma

Pleomorphic Liposarcoma

Well-differentiated Liposarcoma

Inflammatory Liposarcoma

Lipoma-like Liposarcoma

Sclerosing Liposarcoma

Lymphangiosarcoma

Malignant Giant Cell Tumor of Tendon Sheath

Malignant Glomus Tumor (Glomangiosarcoma)

Malignant Extrarenal Rhabdoid Tumor Malignant Hemangiopericytoma

Malignant Mesenchymoma

Neural Tumors

Malignant Peripheral Nerve Sheath Tumor (MPNST)

Malignant Triton Tumor Epithelioid MPNST

Glandular MPNST

Reticulum Cell Sarcoma (Lymphoma of bone)

Skeletal Muscle Tumors

Ectomesenchymoma

Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma Botryoid Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Pleomorphic Rhabdomyosarcoma

Spindle Cell Rhabdomyosarcoma

Small Round Cell Sarcoma

Histiocytosis

Metastatic Neuroblastoma

Metastatic Undifferentiated Carcinoma

Multiple Myeloma

Osteomyelitis

Small Cell Osteosarcoma

Smooth Muscle Tumors

Epithelioid Leiomyosarcoma

Leiomyosarcoma

Solitary Fibrous Tumor

Spindle Cell Hemangioendothelioma

Synovial Sarcoma

Biphasic Synovial Sarcoma Monophasic Synovial Sarcoma

Spinal Cord Cancer Spindle Cell Thyroid Cancer Squamous Cell Cancer (Non-Skin) Squamous Cell Lung Cancer Squamous Cell Skin Cancer

Stem Cell Transplantation

# Stomach Cancer, including:

Stomach Cancer, Adenocanthoma

Stomach Cancer, Adenocarcinoma

Stomach Cancer, Adenosquamous Carcinoma

Stomach Cancer, Gastric Carcinoid

51

Stomach Cancer, Gastric Leiomyosarcoma
Stomach Cancer, Gastric Lymphoma
Stomach Cancer, Gastric Plasmacytoma
Stomach Cancer, Linitis Plastica
Stomach Cancer, Scirrhous Carcinoma
Stomach Cancer, Signet Ring Cell
Stomach Cancer, Mucinous Adenocarcinoma

Stomach Cancer, Mixed adeno- and Choriocarcinoma

Stomach Cancer, Papillary Adenocarcinoma Stomach Cancer, Squamous Cell Carcinoma Stomach Cancer with Bone Metastases

Superficial Bladder Cancer

**Sweat Glands Cancer** 

-T-

T-Cell Leukemia

T-Cell Lymphoma, Cutaneous

Testicular Cancer, Adenocarcinoma of the Rete Testis

Testicular Cancer, Carcinoma In Situ

Testicular Cancer, Choriocarcinoma

Testicular Cancer, Epidermoid Cyst

Testicular Cancer, Germ Cell

Testicular Cancer, Gonadoblastoma

Testicular Cancer, Granulosa Cell Tumors

Testicular Cancer, Leydig Cell Tumors

Testicular Cancer, Lymphoma

Testicular Cancer, Mesothelioma

Testicular Cancer, Metastatic Carcinoma

## Testicular Cancer, Non-Seminoma:

Choriocarcinoma

Embryonal Carcinoma

Teratoma

Immature

Mature

With Malignant Differentiation

Yolk Sac

#### Testicular Cancer, Seminoma:

Anaplastic

Atypical

**Typical** 

#### Testicular Cancer, Sarcomas

# Testicular Cancer, Sertoli Cell Tumors:

Classic

Large Cell Calcifying

Sclerosing

Testicular Cancer, Stage I

Testicular Cancer, Stage II

Testicular Cancer, Stage III

Thalamus (Thalamic) Brain Tumor

Thymoma

#### Thymus Cancer, including:

Thymic Carcinoid

Thymic Carcinoma

53

Clear-Cell Carcinoma

Lymphoepithelioma-like Carcinoma

Mucoepidermoid Carcinoma

Sarcomatoid

Squamous Cell Carcinoma

Thymolipoma

Thymoma

Cortical

Medullary

Mixed

#### Thyroid Cancer:

Papillary thyroid carcinoma with papillary renal neoplasia (PTC-RCC)

Familial nonmedullary thyroid carcinoma (fNMTC)

Familial thyroid tumors with cell oxyphilia (TCO)

Papillary thyroid cancer without oxyphilia

Familial adenomatous polyposis (FAP)

Thyroid malignancy derived from follicular or parafollicular C cells

Medullary thyroid carcinoma (MTC)

Cowden disease

Thyroid Lymphoma

**Tongue Cancer** 

**Tongue Base Cancer** 

Transitional Cell Cencer of Bladder

Transitional Cell Cancer of Renal Pelvis

Transitional Cell Cancer of the Ureter

Transition Cell Cancer of the Urethra

**Tuberous Sclerosis (Bourneville Disease)** 

**Tylosis** 

54

-U-

# **Unknown Primary Cancer Ureter Cancer**

#### **Urethra Cancer:**

Adenocarcinoma Clear Cell

Melanoma

Meianoma

Squamous Cell

Transitional Cell

Undifferentiated

Urethra Cancer, Carcinoma of Bulbomembranous Urethra

Urethra Cancer, Carcinoma of Distal Urethra

Urethra Cancer, Carcinoma of Prostatic Urethra

Urethra Cancer, Carcinoma of Proximal Urethra

**Uterine Cancer** 

Uterine Cancer, Endometrial

Uterine Cancer, Carcinosarcoma

Uterine Cancer, Leiomyosarcoma

**Uterine Cancer, Papillary Serous** 

Uterine Cancer, Sarcoma

Uterine Cancer, Stage I

Uterine Cancer, Stage II

**Uterine Cancer, Stage III** 

Uterine Cancer, Stage IV

Uterine Sarcoma

-V-

#### Vagina Cancer:

Adenocarcinomas

Adenosquamous

Clear Cell

Mucinous

Papillary

Undifferentiated

Primary Vaginal Melanomas

Sarcoma

Embryonal Rhabdomyosarcoma (Sarcoma Botryoides)

Endometrial Stromal Sarcoma

Leiomyosarcoma

Malignant Mixed Mullerian Tumor

Small Cell Carcinoma

Squamous Cell Carcinoma

Keratinizing

Nonkeratinizing

Vaginal Intraepithelial Neoplasia

Verrucous Carcinoma

#### **Vocal Cord Cancer**

#### **Vulva Cancer:**

Adenocarcinoma

Anaplastic Carcinomas

Large Immature Cells

Spindle Sarcomatoid Cells

Small Cells

Bartholin's Gland Carcinoma

Adenocarcinoma

Adenoid Cystic Carcinoma

Squamous Cell Carcinoma

Transitional Cell Carcinoma

Basal Cell Carcinoma

Lichen Sclerosis

Malignant Melanoma

Paget's Lesions

Primary Mammary Adenocarcinoma

Sebaceous Carcinoma

Squamous Cell Carcinoma

Squamous Hyperplasia Verrucous Carcinoma Vulvar Intraepithelial Neoplasia Vulvar Sarcoma

Angiosarcoma
Epithelioid Sarcoma
Leiomyosarcoma
Neurofibrosarcoma
Rhabdomyosarcoma

WO 2007/053573 PCT/US2006/042367

57

-W-

Waldenstrom's Macroglobulinemia Warthin's Tumor Wilms' Tumor (Child)

-Z-

Zollinger-Ellison Syndrome

#### **EXAMPLES**

[0048] Patients with inoperable hepatocellular carcinoma (HCC), no prior systemic treatment, and Child–Pugh (CP) score of A or B, received oral sorafenib at 400 mg bid continuously in 4-week cycles. Tumor response was assessed every two cycles using modified WHO criteria and independent radiologic review. Plasma samples were collected to evaluate the pharmacokinetics (PK) of sorafenib. Biomarker assays were performed in selected patients. These included phospho-ERK levels via immunohistochemistry in pretreatment biopsies, plasma HER-2 /neu analysis, plasma protein proteomics via mass spectrometry, and blood cell RNA expression patterns via Affymetrix GeneChip microarray analysis.

[0049] Results: Of 137 patients who were enrolled (M:F = 97:40; median age 69 years [range 28–86]), 98 (72%) had CP A and 38 (28%) CP B. Based on independent radiologic review, three (2.2%) patients achieved a partial response, eight (5.8%) achieved a minor response, and 46 (33.6%) had stable disease for at least 16 weeks as best response. Investigator-assessed median TTP was 4.2 months, and median overall survival was 9.2 months. The most common grade 3/4 drug-related toxicities which led to dose delay and/or modification were diarrhea (4.4%), hand-foot skin reaction (5.1%) and fatigue (5.8%). There were no pharmacokinetic differences between CP A and B patients. A correlation was found between pretreatment tumor phospho-ERK levels and patient response.

#### What we claim:

- 1. A method of treating a cancer listed in Table 1 in a subject in need thereof, comprising, administering an effective amount of sorafenib to said subject having said cancer
- 2. A method of claim 1, wherein said cancer is Abdominal Fibromatosis
- 3. A method of claim 1, wherein said cancer is acanthosis nigricans
- 4. A method of claim 1, wherein said cancer is Acinar Adenocarcinoma
- 5. A method of claim 1, wherein said cancer is Acquired ichthyosis
- 6. A method of claim 1, wherein said cancer is Acrokeratosis paraneoplastica
- 7. A method of claim 1, wherein said cancer is Actinic keratoses
- 8. A method of claim 1, wherein said cancer is Acute polyradiculoneuropathy
- 9. A method of claim 1, wherein said cancer is Adenocarcinoma
- 10. A method of claim 1, wherein said cancer is Adenocarcinoma Lung Cancer
- 11. A method of claim 1, wherein said cancer is adenocarcinoma of the colon, stomach, or pancreas
- 12. A method of claim 1, wherein said cancer is Adenocarcinomas Solid Adenocarcinoma with Mucin Formation
- 13. A method of claim 1, wherein said cancer is Adenocystic Carcinoma
- 14. A method of claim 1, wherein said cancer is Adenoid Cystic Breast Cancer
- 15. A method of claim 1, wherein said cancer is Adenoid Cystic Carcinoma
- 16. A method of claim 1, wherein said cancer is Adenomatoid
- 17. A method of claim 1, wherein said cancer is Adenosquamous
- 18. A method of claim 1, wherein said cancer is Adenosquamous Carcinoma
- 19. A method of claim 1, wherein said cancer is Adrenal Gland Cancer Cortical Adenoma
- 20. A method of claim 1, wherein said cancer is Adrenal Gland Cancer:
- 21. A method of claim 1, wherein said cancer is Adult Fibrosarcoma
- 22. A method of claim 1, wherein said cancer is Advanced Breast Cancer
- 23. A method of claim 1, wherein said cancer is Aggressive Breast Cancer
- 24. A method of claim 1, wherein said cancer is AIDS related disorders:
- 25. A method of claim 1, wherein said cancer is AIDS-related disorders Kaposi's sarcoma
- 26. A method of claim 1, wherein said cancer is AIDS-related disorders, lymphoma
- 27. A method of claim 1, wherein said cancer is Alveolar Rhabdomyosarcoma

- 28. A method of claim 1, wherein said cancer is Ameloblastoma
- 29. A method of claim 1, wherein said cancer is Anal (Anus) Cancer, including:
- 30. A method of claim 1, wherein said cancer is Anal Cancer Adenocarcinomas
- 31. A method of claim 1, wherein said cancer is Anal Cancer Bowen's Disease
- 32. A method of claim 1, wherein said cancer is Anal Cancer Early-Stage (Superficial)
- 33. A method of claim 1, wherein said cancer is Anal Cancer Intermediate-Stage I
- 34. A method of claim 1, wherein said cancer is Anal Cancer Intermediate-Stage II
- 35. A method of claim 1, wherein said cancer is Anal Cancer Intermediate-Stage III
- 36. A method of claim 1, wherein said cancer is Anal Cancer Intraepithelial Neoplasia
- 37. A method of claim 1, wherein said cancer is Anal Cancer Metastatic, Advanced-Stage IV
- 38. A method of claim 1, wherein said cancer is Anal Cancer Paget's Disease
- 39. A method of claim 1, wherein said cancer is Anal Cancer Small Cell Cancers
- 40. A method of claim 1, wherein said cancer is Anal Cancer Squamous Cell Carcinoma
- 41. A method of claim 1, wherein said cancer is Anaplastic
- 42. A method of claim 1, wherein said cancer is Anaplastic Carcinomas
- 43. A method of claim 1, wherein said cancer is Angiomatoid Fibrous Histiocytoma
- 44. A method of claim 1, wherein said cancer is Angiosarcoma
- 45. A method of claim 1, wherein said cancer is Appendix Cancer (Appendiceal Cancer)
- 46. A method of claim 1, wherein said cancer is Ascites, Malignant
- 47. A method of claim 1, wherein said cancer is astleman's disease
- 48. A method of claim 1, wherein said cancer is Astrocytoma
- 49. A method of claim 1, wherein said cancer is Atypical
- 50. A method of claim 1, wherein said cancer is Atypical Adenomatous Hyperplasia
- 51. A method of claim 1, wherein said cancer is Atypical fibroxanthoma
- 52. A method of claim 1, wherein said cancer is Atypical Lipoma
- 53. A method of claim 1, wherein said cancer is Barrett's Esophagus
- 54. A method of claim 1, wherein said cancer is Bartholin Gland Cancer
- 55. A method of claim 1, wherein said cancer is Bartholin's Gland Carcinoma
- 56. A method of claim 1, wherein said cancer is Basal Cell Carcinoma

- 57. A method of claim 1, wherein said cancer is Basal Cell- nodular, nevoid, superficial, morpheaform (also termed aggressive-growth BCC or infiltrative BCC), pigmented, cystic BCC, and fibroepithelioma of Pinkus (FEP)
- 58. A method of claim 1, wherein said cancer is Basal Cell Skin Cancer
- 59. A method of claim 1, wherein said cancer is B-Cell Lymphoma
- 60. A method of claim 1, wherein said cancer is Bednar Tumor
- 61. A method of claim 1, wherein said cancer is Bilateral Breast Cancer
- 62. A method of claim 1, wherein said cancer is Bile Duct Cancer
- 63. A method of claim 1, wherein said cancer is Biphasic Synovial Sarcoma
- 64. A method of claim 1, wherein said cancer is Bladder Cancer Metastases
- 65. A method of claim 1, wherein said cancer is Bladder Cancer Muscle-Invasive
- 66. A method of claim 1, wherein said cancer is Bladder Cancer Small Cell
- 67. A method of claim 1, wherein said cancer is Bladder Cancer Superficial
- 68. A method of claim 1, wherein said cancer is Bladder Cancer:
- 69. A method of claim 1, wherein said cancer is Bone Cancer Bone Marrow Transplantation
- 70. A method of claim 1, wherein said cancer is Bone Cancer Bone Metastases
- 71. A method of claim 1, wherein said cancer is Bone Cancer Chondrosarcoma
- 72. A method of claim 1, wherein said cancer is Bone Cancer Chordoma
- 73. A method of claim 1, wherein said cancer is Bone Cancer Ewing's Sarcoma (Child)
- 74. A method of claim 1, wherein said cancer is Bone Cancer Giant Cell
- 75. A method of claim 1, wherein said cancer is Bone Cancer Mesenchymal Chondrosarcoma
- 76. A method of claim 1, wherein said cancer is Bone Cancer Osteosarcoma
- 77. A method of claim 1, wherein said cancer is Bone Cancer:
- 78. A method of claim 1, wherein said cancer is Borderline Ovarian Cancer
- 79. A method of claim 1, wherein said cancer is Botryoid Rhabdomyosarcoma
- 80. A method of claim 1, wherein said cancer is Bowen's Disease
- 81. A method of claim 1, wherein said cancer is Brain Tumors Adult
- 82. A method of claim 1, wherein said cancer is Brain Tumors Astrocytoma
- 83. A method of claim 1, wherein said cancer is Brain Tumors Brainstem
- 84. A method of claim 1, wherein said cancer is Brain Tumors Brainstem Glioma
- 85. A method of claim 1, wherein said cancer is Brain Tumors Cavernous Sinus

- 86. A method of claim 1, wherein said cancer is Brain Tumors Child
- 87. A method of claim 1, wherein said cancer is Brain Tumors Chondroma
- 88. A method of claim 1, wherein said cancer is Brain Tumors Ependymoma
- 89. A method of claim 1, wherein said cancer is Brain Tumors Glioblastoma
- 90. A method of claim 1, wherein said cancer is Brain Tumors Glioma
- 91. A method of claim 1, wherein said cancer is Brain Tumors Gliomatosis
- 92. A method of claim 1, wherein said cancer is Brain Tumors Hemangiopericytoma
- 93. A method of claim 1, wherein said cancer is Brain Tumors Medulloblastoma
- 94. A method of claim 1, wherein said cancer is Brain Tumors Oligodendroglioma
- 95. A method of claim 1, wherein said cancer is Brain Tumors Pineoblastoma / Pinealoma
- 96. A method of claim 1, wherein said cancer is Brain Tumors Primary Central Nervous System Lymphoma
- 97. A method of claim 1, wherein said cancer is Brain Tumors Thalamic
- 98. A method of claim 1, wherein said cancer is Brain Tumors:
- 99. A method of claim 1, wherein said cancer is Breast Cancer Adenoid Cystic
- 100. A method of claim 1, wherein said cancer is Breast Cancer Advanced
- 101. A method of claim 1, wherein said cancer is Breast Cancer Aggressive
- 102. A method of claim 1, wherein said cancer is Breast Cancer Apocrine Carcinoma
- 103. A method of claim 1, wherein said cancer is Breast Cancer Bilateral (in both breasts)
- 104. A method of claim 1, wherein said cancer is Breast Cancer Breast Reconstruction
- 105. A method of claim 1, wherein said cancer is Breast Cancer Comedo Type
- 106. A method of claim 1, wherein said cancer is Breast Cancer Comedo Type Breast Cancer
- 107. A method of claim 1, wherein said cancer is Breast Cancer Ductal Carcinoma In Situ
- 108. A method of claim 1, wherein said cancer is Breast Cancer Ductal Carcinoma Invasive
- 109. A method of claim 1, wherein said cancer is Breast Cancer Early Stage
- 110. A method of claim 1, wherein said cancer is Breast Cancer Early Stage Breast Cancer
- 111. A method of claim 1, wherein said cancer is Breast Cancer Estrogen-Negative
- 112. A method of claim 1, wherein said cancer is Breast Cancer Estrogen-Negative Breast Cancer
- 113. A method of claim 1, wherein said cancer is Breast Cancer High-Risk
- 114. A method of claim 1, wherein said cancer is Breast Cancer in Pregnancy

- 115. A method of claim 1, wherein said cancer is Breast Cancer Inflammatory
- 116. A method of claim 1, wherein said cancer is Breast Cancer Inflammatory Breast Cancer
- 117. A method of claim 1, wherein said cancer is Breast Cancer Invasive Breast Cancer
- 118. A method of claim 1, wherein said cancer is Breast Cancer Lobular Breast Cancer
- 119. A method of claim 1, wherein said cancer is Breast Cancer Lobular Carcinoma In situ (LCIS)
- 120. A method of claim 1, wherein said cancer is Breast Cancer Lobular, Invasive
- 121. A method of claim 1, wherein said cancer is Breast Cancer Lymphoma
- 122. A method of claim 1, wherein said cancer is Breast Cancer Medullary
- 123. A method of claim 1, wherein said cancer is Breast Cancer Medullary Breast Cancer
- 124. A method of claim 1, wherein said cancer is Breast Cancer Metachronous Bilateral
- 125. A method of claim 1, wherein said cancer is Breast Cancer Microinvasive
- 126. A method of claim 1, wherein said cancer is Breast Cancer Microinvasive Breast Cancer
- 127. A method of claim 1, wherein said cancer is Breast Cancer Mucinous
- 128. A method of claim 1, wherein said cancer is Breast Cancer Mucinous Breast Cancer
- 129. A method of claim 1, wherein said cancer is Breast Cancer Node-Negative
- 130. A method of claim 1, wherein said cancer is Breast Cancer Node-Negative Breast Cancer
- 131. A method of claim 1, wherein said cancer is Breast Cancer Node-Positive
- 132. A method of claim 1, wherein said cancer is Breast Cancer Node-Positive Breast Cancer
- 133. A method of claim 1, wherein said cancer is Breast Cancer Nonepithelial Neoplasms Phyllodes Sarcomas
- 134. A method of claim 1, wherein said cancer is Breast Cancer Nonepithelial Neoplasms Phyllodes Tumors
- 135. A method of claim 1, wherein said cancer is Breast Cancer Occult Breast Cancer with Lymphatic Metastasis
- 136. A method of claim 1, wherein said cancer is Breast Cancer Occult with Lymphatic Metastasis
- 137. A method of claim 1, wherein said cancer is Breast Cancer Paget's Disease of the Nipple
- 138. A method of claim 1, wherein said cancer is Breast Cancer Papillary
- 139. A method of claim 1, wherein said cancer is Breast Cancer Papillary Breast Cancer
- 140. A method of claim 1, wherein said cancer is Breast Cancer Postmenopausal

- 141. A method of claim 1, wherein said cancer is Breast Cancer Premenopausal
- 142. A method of claim 1, wherein said cancer is Breast Cancer Recurrent
- 143. A method of claim 1, wherein said cancer is Breast Cancer Recurrent Breast Cancer
- 144. A method of claim 1, wherein said cancer is Breast Cancer Sarcoma
- 145. A method of claim 1, wherein said cancer is Breast Cancer Sarcoma of the Breast
- 146. A method of claim 1, wherein said cancer is Breast Cancer Secretory (juvenile)

  Carcinoma
- 147. A method of claim 1, wherein said cancer is Breast Cancer Squamous
- 148. A method of claim 1, wherein said cancer is Breast Cancer Squamous Cell Breast Cancer
- 149. A method of claim 1, wherein said cancer is Breast Cancer Stage I
- 150. A method of claim 1, wherein said cancer is Breast Cancer Stage II
- 151. A method of claim 1, wherein said cancer is Breast Cancer Stage III
- 152. A method of claim 1, wherein said cancer is Breast Cancer Stage IV
- 153. A method of claim 1, wherein said cancer is Breast Cancer Synchronous Bilateral Breast Cancer
- 154. A method of claim 1, wherein said cancer is Breast Cancer Tubular
- 155. A method of claim 1, wherein said cancer is Breast Cancer Tubular Breast Cancer
- 156. A method of claim 1, wherein said cancer is Breast Cancer Ulcerating
- 157. A method of claim 1, wherein said cancer is Breast Cancer Ulcerating Breast Cancer
- 158. A method of claim 1, wherein said cancer is Breast Cancer with Bladder Metastases
- 159. A method of claim 1, wherein said cancer is Breast Cancer with Bone and Lung Metastases
- 160. A method of claim 1, wherein said cancer is Breast Cancer with Bone Metastases
- 161. A method of claim 1, wherein said cancer is Breast Cancer with Brain and Liver Metastases
- 162. A method of claim 1, wherein said cancer is Breast Cancer with Brain Metastases
- 163. A method of claim 1, wherein said cancer is Breast Cancer with Central Nervous System Metastases
- 164. A method of claim 1, wherein said cancer is Breast Cancer with Liver Metastases
- 165. A method of claim 1, wherein said cancer is Breast Cancer with Lung Metastases
- 166. A method of claim 1, wherein said cancer is Breast Cancer with Lymph Node Metastases
- 167. A method of claim 1, wherein said cancer is Breast Cancer with Lymphangitic Metastasis
- 168. A method of claim 1, wherein said cancer is Breast Cancer with Lymphatic Metastases

- 169. A method of claim 1, wherein said cancer is Breast Cancer with Meningeal Metastases
- 170. A method of claim 1, wherein said cancer is Breast Cancer with Pericardial Effusion
- 171. A method of claim 1, wherein said cancer is Breast Cancer with Pleura Metastases
- 172. A method of claim 1, wherein said cancer is Breast Cancer with Pleural Effusion
- 173. A method of claim 1, wherein said cancer is Breast Cancer with Skin Metastases
- 174. A method of claim 1, wherein said cancer is Breast Cancer with Spine Metastases
- 175. A method of claim 1, wherein said cancer is Breast Cancer with Stomach Metastases
- 176. A method of claim 1, wherein said cancer is Breast Cancer, Nonepithelial Neoplasms:
- 177. A method of claim 1, wherein said cancer is Breast Cancers Including:
- 178. A method of claim 1, wherein said cancer is Bronchial Cancer
- 179. A method of claim 1, wherein said cancer is Bronchioalveolar Lung Cancer
- 180. A method of claim 1, wherein said cancer is Burkitt's Lymphoma
- 181. A method of claim 1, wherein said cancer is Buttock Cancer
- 182. A method of claim 1, wherein said cancer is Cancer of Unknown Primary Site (CUPS)
- 183. A method of claim 1, wherein said cancer is Carcinoid
- 184. A method of claim 1, wherein said cancer is Carcinoid of the Appendix
- 185. A method of claim 1, wherein said cancer is Carcinoid of the Colon
- 186. A method of claim 1, wherein said cancer is Carcinoid of the Pancreas
- 187. A method of claim 1, wherein said cancer is Carcinoid of the Rectum
- 188. A method of claim 1, wherein said cancer is Carcinoid of the Stomach
- 189. A method of claim 1, wherein said cancer is Carcinoid Syndrome
- 190. A method of claim 1, wherein said cancer is Carcinoid Tumor
- 191. A method of claim 1, wherein said cancer is Carcinoid Tumors, Atypical
- 192. A method of claim 1, wherein said cancer is Carcinoid Tumors, Typical
- 193. A method of claim 1, wherein said cancer is Carcinoma Metastatic to Skin
- 194. A method of claim 1, wherein said cancer is Carcinoma of Unknown Primary
- 195. A method of claim 1, wherein said cancer is Carcinosarcoma
- 196. A method of claim 1, wherein said cancer is Carcinosarcoma of the Ovary
- 197. A method of claim 1, wherein said cancer is Carcinosarcoma of the Uterus
- 198. A method of claim 1, wherein said cancer is Carney's Triad
- 199. A method of claim 1, wherein said cancer is Cavernous Sinus Cancer

- 200. A method of claim 1, wherein said cancer is Cecum Cancer
- 201. A method of claim 1, wherein said cancer is Central Nervous System Cancers Acoustic Neuromas (Vestibular Schwannomas)
- 202. A method of claim 1, wherein said cancer is Central Nervous System Cancers Astrocytoma, e.g., WHO grade III Anaplastic Astrocytoma, and WHO grade IV
- 203. A method of claim 1, wherein said cancer is Central Nervous System Cancers Astrocytomas
- 204. A method of claim 1, wherein said cancer is Central Nervous System Cancers Atypical Teratoid/Rhabdoid Tumors
- 205. A method of claim 1, wherein said cancer is Central Nervous System Cancers Chordoma and Chondrosarcoma
- 206. A method of claim 1, wherein said cancer is Central Nervous System Cancers Choroid Plexus Papilloma and Carcinoma
- 207. A method of claim 1, wherein said cancer is Central Nervous System Cancers Choroid Plexus Tumor
- 208. A method of claim 1, wherein said cancer is Central Nervous System Cancers Craniopharyngioma
- 209. A method of claim 1, wherein said cancer is Central Nervous System Cancers Cystic Cerebellar Astrocytomas
- 210. A method of claim 1, wherein said cancer is Central Nervous System Cancers Diffuse, Fibrillary Astrocytomas e.g., World Health Organization (WHO) Grade II
- 211. A method of claim 1, wherein said cancer is Central Nervous System Cancers Ependymoblastoma
- 212. A method of claim 1, wherein said cancer is Central Nervous System Cancers Ependymoma- Ellular, Papillary, Clear Cell, Tanycytic, Myxopapillary
- 213. A method of claim 1, wherein said cancer is Central Nervous System Cancers Germinomas
- 214. A method of claim 1, wherein said cancer is Central Nervous System Cancers Glioblastoma (GBM)
- 215. A method of claim 1, wherein said cancer is Central Nervous System Cancers Gliomas Optic, Chiasmal, and Hypothalamic

- 216. A method of claim 1, wherein said cancer is Central Nervous System Cancers Glomus Jugulare tumors (Paragangliomas)
- 217. A method of claim 1, wherein said cancer is Central Nervous System Cancers Gorlin's, Turcot, and Li-Fraumeni syndromes
- 218. A method of claim 1, wherein said cancer is Central Nervous System Cancers Hemangioblastomas
- 219. A method of claim 1, wherein said cancer is Central Nervous System Cancers Hemangioblastomas
- 220. A method of claim 1, wherein said cancer is Central Nervous System Cancers Medulloblastoma
- 221. A method of claim 1, wherein said cancer is Central Nervous System Cancers Medulloepithelioma
- 222. A method of claim 1, wherein said cancer is Central Nervous System Cancers -Meningioma- Atypical and Malignant, Parasagittal, Falx, Olfactory Groove, Tuberculum Sellae, Sphenoid Ridge, Cerebellopontine Angle
- 223. A method of claim 1, wherein said cancer is Central Nervous System Cancers Neuroblastoma
- 224. A method of claim 1, wherein said cancer is Central Nervous System Cancers Neurofibromas
- 225. A method of claim 1, wherein said cancer is Central Nervous System Cancers Oligoastrocytoma- Anaplastic, differentiated
- 226. A method of claim 1, wherein said cancer is Central Nervous System Cancers Oligodendroglioma- Anaplastic, differentiated
- 227. A method of claim 1, wherein said cancer is Central Nervous System Cancers Pilocytic Astrocytoma
- 228. A method of claim 1, wherein said cancer is Central Nervous System Cancers Pineal Parenchymal Tumors
- 229. A method of claim 1, wherein said cancer is Central Nervous System Cancers Pineoblastoma
- 230. A method of claim 1, wherein said cancer is Central Nervous System Cancers Pituitary Adenoma

- 231. A method of claim 1, wherein said cancer is Central Nervous System Cancers Pleomorphic Xanthoastrocytoma
- 232. A method of claim 1, wherein said cancer is Central Nervous System Cancers Schwannoma
- 233. A method of claim 1, wherein said cancer is Central Nervous System Cancers Spinal Axis Tumors
- 234. A method of claim 1, wherein said cancer is Central Nervous System Cancers Subependymal Giant Cell Astrocytomas
- 235. A method of claim 1, wherein said cancer is Central Nervous System Cancers Supratentorial Parenchymal tumors
- 236. A method of claim 1, wherein said cancer is Central Nervous System Cancers:
- 237. A method of claim 1, wherein said cancer is Central Nervous System Lymphoma
- 238. A method of claim 1, wherein said cancer is Centrocytic Lymphoma
- 239. A method of claim 1, wherein said cancer is Cerebral Astrocytoma
- 240. A method of claim 1, wherein said cancer is Cervical Cancer, Adenocarcinoma In Situ Adenoid Basal Carcinoma
- 241. A method of claim 1, wherein said cancer is Cervical Cancer, Adenocarcinoma In Situ Adenoma Malignum
- 242. A method of claim 1, wherein said cancer is Cervical Cancer, Adenocarcinoma In Situ Adenosquamous Carcinoma
- 243. A method of claim 1, wherein said cancer is Cervical Cancer, Adenocarcinoma In Situ Glassy Cell Carcinoma
- 244. A method of claim 1, wherein said cancer is Cervical Cancer, Adenocarcinoma In Situ-Papillary Serous Carcinoma
- 245. A method of claim 1, wherein said cancer is Cervix Cancer (Cervical Cancer), Adenocarcinoma In Situ:
- 246. A method of claim 1, wherein said cancer is Cervix Cancer (Cervical Cancer), Anaplastic Small Cell Carcinoma
- 247. A method of claim 1, wherein said cancer is Cervix Cancer (Cervical Cancer), Cervical Intraepithelial Neoplasia

- 248. A method of claim 1, wherein said cancer is Cervix Cancer (Cervical Cancer), Malignant Mixed Müllerian Tumors
- 249. A method of claim 1, wherein said cancer is Cervix Cancer (Cervical Cancer):
- 250. A method of claim 1, wherein said cancer is Chest Tumors (Mediastinum Tumors)
- 251. A method of claim 1, wherein said cancer is Chiasmal Glioma
- 252. A method of claim 1, wherein said cancer is Childhood Cancers
- 253. A method of claim 1, wherein said cancer is Chondroma, Intracranial
- 254. A method of claim 1, wherein said cancer is Chondrosarcoma
- 255. A method of claim 1, wherein said cancer is Chondrosarcoma Central
- 256. A method of claim 1, wherein said cancer is Chondrosarcoma Clear Cell
- 257. A method of claim 1, wherein said cancer is Chondrosarcoma Differentiated
- 258. A method of claim 1, wherein said cancer is Chondrosarcoma Mesenchymal
- 259. A method of claim 1, wherein said cancer is Chondrosarcoma Peripheral
- 260. A method of claim 1, wherein said cancer is Chondrosarcoma:
- 261. A method of claim 1, wherein said cancer is Chordoma
- 262. A method of claim 1, wherein said cancer is Chorioadenoma Destruens
- 263. A method of claim 1, wherein said cancer is Choriocarcinoma
- 264. A method of claim 1, wherein said cancer is Choriocarcinoma, Cytotrophoblast
- 265. A method of claim 1, wherein said cancer is Choriocarcinoma, Syncytiotrophoblast
- 266. A method of claim 1, wherein said cancer is Choriocarcinoma:
- 267. A method of claim 1, wherein said cancer is Choroid Plexus Carcinoma
- 268. A method of claim 1, wherein said cancer is Choroidal Melanoma
- 269. A method of claim 1, wherein said cancer is Chronic Leukemia
- 270. A method of claim 1, wherein said cancer is Chronic Lymphocytic Leukemia (CLL)
- 271. A method of claim 1, wherein said cancer is Chronic Myelogenous Leukemia (CML)
- 272. A method of claim 1, wherein said cancer is Clear Cell
- 273. A method of claim 1, wherein said cancer is Clear Cell Ovarian Cancer
- 274. A method of claim 1, wherein said cancer is Clear Cell Sarcoma
- 275. A method of claim 1, wherein said cancer is Clear-Cell Carcinoma
- 276. A method of claim 1, wherein said cancer is CNS Lymphoma

- 277. A method of claim 1, wherein said cancer is Colon Cancer Adenocarcinoma of the Colon Mucinous (Colloid)
- 278. A method of claim 1, wherein said cancer is Colon Cancer Adenocarcinoma of the Colon Signet Ring
- 279. A method of claim 1, wherein said cancer is Colon Cancer Adenomatous Polyps
- 280. A method of claim 1, wherein said cancer is Colon Cancer Amine Precursor Uptake and Decarboxylation Tumor
- 281. A method of claim 1, wherein said cancer is Colon Cancer Cecum
- 282. A method of claim 1, wherein said cancer is Colon Cancer Hamartomatous Polyposis Syndrome
- 283. A method of claim 1, wherein said cancer is Colon Cancer Hereditary Nonpolyposis

  Colorectal Cancer
- 284. A method of claim 1, wherein said cancer is Colon Cancer Lymphoma
- 285. A method of claim 1, wherein said cancer is Colon Cancer Lymphoma B-Cell
- 286. A method of claim 1, wherein said cancer is Colon Cancer Lymphoma T-Cell
- 287. A method of claim 1, wherein said cancer is Colon Cancer Mucinous
- 288. A method of claim 1, wherein said cancer is Colon Cancer Neuroendocrine Carcinoma Extrapulmonary Small Cell
- 289. A method of claim 1, wherein said cancer is Colon Cancer Neuroendocrine Carcinoma High-grade
- 290. A method of claim 1, wherein said cancer is Colon Cancer Neuroendocrine Carcinoma Oat Cell
- 291. A method of claim 1, wherein said cancer is Colon Cancer Neuroendocrine Carcinoma Well-differentiated Carcinoid
- 292. A method of claim 1, wherein said cancer is Colon Cancer Polyps
- 293. A method of claim 1, wherein said cancer is Colon Cancer Recurrent
- 294. A method of claim 1, wherein said cancer is Colon Cancer Stage A
- 295. A method of claim 1, wherein said cancer is Colon Cancer Stage B
- 296. A method of claim 1, wherein said cancer is Colon Cancer Stage C
- 297. A method of claim 1, wherein said cancer is Colon Cancer Stage D
- 298. A method of claim 1, wherein said cancer is Colon Cancer Stage I (Dukes' A)

- 299. A method of claim 1, wherein said cancer is Colon Cancer Stage II (Dukes' B)
- 300. A method of claim 1, wherein said cancer is Colon Cancer Stage III (Dukes' C)
- 301. A method of claim 1, wherein said cancer is Colon Cancer Stage IV
- 302. A method of claim 1, wherein said cancer is Colon Cancer Including:
- 303. A method of claim 1, wherein said cancer is Colon Cancer with Bone Metastases
- 304. A method of claim 1, wherein said cancer is Colon Cancer with Brain Metastases
- 305. A method of claim 1, wherein said cancer is Colon Cancer with Buttocks Metastases
- 306. A method of claim 1, wherein said cancer is Colon Cancer with Liver and Lung Metastases
- 307. A method of claim 1, wherein said cancer is Colon Cancer with Liver Metastases
- 308. A method of claim 1, wherein said cancer is Colon Cancer with Lung Metastases
- 309. A method of claim 1, wherein said cancer is Colon Cancer with Ovarian Metastases
- 310. A method of claim 1, wherein said cancer is Colon Cancer with Skin Metastases
- 311. A method of claim 1, wherein said cancer is Colon Cancer, Neuroendocrine Carcinoma:
- 312. A method of claim 1, wherein said cancer is Colorectal Cancer, Colon Cancer
- 313. A method of claim 1, wherein said cancer is Cortical
- 314. A method of claim 1, wherein said cancer is Cowden disease
- 315. A method of claim 1, wherein said cancer is Craniopharyngioma
- 316. A method of claim 1, wherein said cancer is Cutaneous paraneoplastic syndrom
- 317. A method of claim 1, wherein said cancer is Cutaneous T-Cell Lymphoma
- 318. A method of claim 1, wherein said cancer is DCIS Ductal Carcinoma In Situ
- 319. A method of claim 1, wherein said cancer is Dedifferentiated Liposarcoma
- 320. A method of claim 1, wherein said cancer is Deep Fibromatoses
- 321. A method of claim 1, wherein said cancer is Dermatofibroma
- 322. A method of claim 1, wherein said cancer is Dermatofibrosarcoma Protuberans
- 323. A method of claim 1, wherein said cancer is Dermatomyositis
- 324. A method of claim 1, wherein said cancer is Desmoid Tumor
- 325. A method of claim 1, wherein said cancer is Desmoplastic trichoepithelioma
- 326. A method of claim 1, wherein said cancer is Desmoplastic Tumor
- 327. A method of claim 1, wherein said cancer is Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
- 328. A method of claim 1, wherein said cancer is Diffuse Large B-Cell Lymphoma

- 329. A method of claim 1, wherein said cancer is Diffuse Lymphoma
- 330. A method of claim 1, wherein said cancer is Diffuse, Large-Cell Lymphoma
- 331. A method of claim 1, wherein said cancer is Disseminated peritoneal adenomucinosis
- 332. A method of claim 1, wherein said cancer is Ductal Carcinoma
- 333. A method of claim 1, wherein said cancer is Ductal Carcinoma in Situ (DCIS)
- 334. A method of claim 1, wherein said cancer is Duodenal Cancer
- 335. A method of claim 1, wherein said cancer is Dysgerminoma
- 336. A method of claim 1, wherein said cancer is Early Stage Prostate Cancer
- 337. A method of claim 1, wherein said cancer is Ectomesenchymoma
- 338. A method of claim 1, wherein said cancer is Ectopic Adrenocorticotropic Hormone Syndrome:
- 339. A method of claim 1, wherein said cancer is Embryonal Carcinoma
- 340. A method of claim 1, wherein said cancer is Embryonal Rhabdomyosarcoma
- 341. A method of claim 1, wherein said cancer is Embryonal Rhabdomyosarcoma (Sarcoma Botryoides)
- 342. A method of claim 1, wherein said cancer is Endochodroma
- 343. A method of claim 1, wherein said cancer is Endocrine Cancer Familial Non-MEN MTC (FMTC)
- 344. A method of claim 1, wherein said cancer is Endocrine Cancer Follicular Adenomas
- 345. A method of claim 1, wherein said cancer is Endocrine Cancer MEN 2A
- 346. A method of claim 1, wherein said cancer is Endocrine Cancer MEN 2B
- 347. A method of claim 1, wherein said cancer is Endocrine Cancer Multiple Endocrine Neoplasia Type 1 (MEN 1)
- 348. A method of claim 1, wherein said cancer is Endocrine Cancer Multiple Endocrine Neoplasia Type 2 (MEN 2)
- 349. A method of claim 1, wherein said cancer is Endocrine Cancer Papillary Thyroid Carcinoma
- 350. A method of claim 1, wherein said cancer is Endocrine Cancer Sporadic MTC
- 351. A method of claim 1, wherein said cancer is Endocrine Cancer Sporadic Thyroid Neoplasms
- 352. A method of claim 1, wherein said cancer is Endocrine Cancer:

- 353. A method of claim 1, wherein said cancer is Endometrial Cancer Adenosarcoma
- 354. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors
- 355. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors Clear Cell
- 356. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors Endometrioid
- 357. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors Malignant Mixed Müllerian
- 358. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors Mucinous
- 359. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors Papillary Endometrioid
- 360. A method of claim 1, wherein said cancer is Endometrial Cancer Epithelial Tumors Papillary Serous
- 361. A method of claim 1, wherein said cancer is Endometrial Cancer Mesenchymal Tumors Endometrial Stromal Sarcoma
- 362. A method of claim 1, wherein said cancer is Endometrial Cancer Mesenchymal Tumors Leiomyosarcoma
- 363. A method of claim 1, wherein said cancer is Endometrial Cancer Mesenchymal Tumors:
- 364. A method of claim 1, wherein said cancer is Endometrial Cancer:
- 365. A method of claim 1, wherein said cancer is Endometrial Stromal Sarcoma
- 366. A method of claim 1, wherein said cancer is Ependymoma
- 367. A method of claim 1, wherein said cancer is Epidermoid Carcinoma
- 368. A method of claim 1, wherein said cancer is epithelial
- 369. A method of claim 1, wherein said cancer is Epithelioid Leiomyosarcoma
- 370. A method of claim 1, wherein said cancer is Epithelioid MPNST
- 371. A method of claim 1, wherein said cancer is Epithelioid Sarcoma
- 372. A method of claim 1, wherein said cancer is Epithelioid Sarcoma:
- 373. A method of claim 1, wherein said cancer is Esophagus Cancer (Esophageal Cancer) Adenoid Cystic Carcinoma

- 374. A method of claim 1, wherein said cancer is Esophagus Cancer (Esophageal Cancer) Mucoepidermoid Carcinoma
- 375. A method of claim 1, wherein said cancer is Esophagus Cancer (Esophageal Cancer), Including:
- 376. A method of claim 1, wherein said cancer is Esophagus Cancer of the Gastroesophageal Junction
- 377. A method of claim 1, wherein said cancer is Esthesioneuroblastoma
- 378. A method of claim 1, wherein said cancer is Ewing's Sarcoma
- 379. A method of claim 1, wherein said cancer is Extensive Stage Small Cell Lung Cancer
- 380. A method of claim 1, wherein said cancer is Extraabdominal Fibromatosis
- 381. A method of claim 1, wherein said cancer is Extrahepatic Bile Duct Cancer
- 382. A method of claim 1, wherein said cancer is Extraovarian Peritoneal Serous Papillary Carcinoma
- 383. A method of claim 1, wherein said cancer is Extraovarian Serous Carcinoma
- 384. A method of claim 1, wherein said cancer is Extraskeletal Cartilaginous Tumors
- 385. A method of claim 1, wherein said cancer is Extraskeletal Chondrosarcoma
- 386. A method of claim 1, wherein said cancer is Extraskeletal Ewing's Sarcoma
- 387. A method of claim 1, wherein said cancer is Extraskeletal Osteosarcoma
- 388. A method of claim 1, wherein said cancer is Eye Cancer
- 389. A method of claim 1, wherein said cancer is Eye Cancer, Lymphoma
- 390. A method of claim 1, wherein said cancer is Eye Metastases
- 391. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Adenocarcinomas
- 392. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Carcinoma
- 393. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Eiomyosarcomas
- 394. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Ovarian Cancer
- 395. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Stage I
- 396. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Stage II
- 397. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Stage III
- 398. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Stage IV
- 399. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Transitional cell carcinomas

- 400. A method of claim 1, wherein said cancer is Fallopian Tube Cancer Including:
- 401. A method of claim 1, wherein said cancer is Familial Adenomatous Polyposis
- 402. A method of claim 1, wherein said cancer is Familial adenomatous polyposis (FAP)
- 403. A method of claim 1, wherein said cancer is Familial nonmedullary thyroid carcinoma (fNMTC)
- 404. A method of claim 1, wherein said cancer is Familial thyroid tumors with cell oxyphilia (TCO)
- 405. A method of claim 1, wherein said cancer is Fibrohistiocytic Tumors
- 406. A method of claim 1, wherein said cancer is Fibromatoses
- 407. A method of claim 1, wherein said cancer is Fibromatosis (Desmoid Tumor)
- 408. A method of claim 1, wherein said cancer is Fibrosarcoma
- 409. A method of claim 1, wherein said cancer is Fibrosarcoma See Soft Tissue Sarcomas
- 410. A method of claim 1, wherein said cancer is Fibrous Histiocytoma
- 411. A method of claim 1, wherein said cancer is Fibrous Tumors
- 412. A method of claim 1, wherein said cancer is Follicular Lymphoma
- 413. A method of claim 1, wherein said cancer is Follicular, Small-Cleaved Cell Lymphoma
- 414. A method of claim 1, wherein said cancer is Foregut
- 415. A method of claim 1, wherein said cancer is Gallbladder Cancer Adenocarcinoma
- 416. A method of claim 1, wherein said cancer is Gallbladder Cancer Mucinous Adenocarcinoma
- 417. A method of claim 1, wherein said cancer is Gallbladder Cancer Papillary Adenocarcinoma
- 418. A method of claim 1, wherein said cancer is Gallbladder Cancer Sarcoma
- 419. A method of claim 1, wherein said cancer is Gallbladder Cancer Squamous Cell Carcinoma
- 420. A method of claim 1, wherein said cancer is Gallbladder Cancer, Including:
- 421. A method of claim 1, wherein said cancer is Gardner's Syndrome
- 422. A method of claim 1, wherein said cancer is Gastric Cancer
- 423. A method of claim 1, wherein said cancer is Gastrinoma
- 424. A method of claim 1, wherein said cancer is Gastro-Esophageal (GE Junction) Cancer
- 425. A method of claim 1, wherein said cancer is Gastrointestinal Lymphoma

- 426. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumor
- 427. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors
- 428. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors Autonomic Nerve Tumor
- 429. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors Leiomyoblastoma
- 430. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors Leiomyosarcoma
- 431. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors Pacemaker Call Tumor
- 432. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors Plexosarcoma
- 433. A method of claim 1, wherein said cancer is Gastrointestinal Stromal Tumors (GST):
- 434. A method of claim 1, wherein said cancer is GE Junction Esophageal Cancer
- 435. A method of claim 1, wherein said cancer is Germ Cell Tumor Mediastinum Tumor
- 436. A method of claim 1, wherein said cancer is Germ Cell Tumor Retroperitoneal Tumor
- 437. A method of claim 1, wherein said cancer is Germ Cell Tumor Undescended Testicular Cancer
- 438. A method of claim 1, wherein said cancer is Germ Cell Tumor:
- 439. A method of claim 1, wherein said cancer is Gestational Trophoblastic Disease
- 440. A method of claim 1, wherein said cancer is Giant Cell
- 441. A method of claim 1, wherein said cancer is Giant Cell Bone Tumor
- 442. A method of claim 1, wherein said cancer is Giant Cell Carcinoma
- 443. A method of claim 1, wherein said cancer is Giant Cell Fibroblastoma
- 444. A method of claim 1, wherein said cancer is Glandular MPNST
- 445. A method of claim 1, wherein said cancer is Glioblastoma
- 446. A method of claim 1, wherein said cancer is Glioma
- 447. A method of claim 1, wherein said cancer is Gliomatosis
- 448. A method of claim 1, wherein said cancer is Gonadal Mesothelioma
- 449. A method of claim 1, wherein said cancer is Gorlin's Syndrome (Nevoid Basal Cell Carcinoma Syndrome)

- 450. A method of claim 1, wherein said cancer is Granular Lymphocytic Lymphoma
- 451. A method of claim 1, wherein said cancer is Granulocytic Leukemia
- 452. A method of claim 1, wherein said cancer is Granulosa Cell Ovarian Cancer
- 453. A method of claim 1, wherein said cancer is Hairy Cell Leukemia
- 454. A method of claim 1, wherein said cancer is Head and Neck Cancer
- 455. A method of claim 1, wherein said cancer is Head and Neck Cancer, Adenoid Cystic
- 456. A method of claim 1, wherein said cancer is Head and Neck Cancer, Squamous Cell
- 457. A method of claim 1, wherein said cancer is Heavy-chain disease
- 458. A method of claim 1, wherein said cancer is Hemangioendothelioma
- 459. A method of claim 1, wherein said cancer is Hemangiopericytoma
- 460. A method of claim 1, wherein said cancer is Hepatocelluar Carcinoma
- 461. A method of claim 1, wherein said cancer is High-Grade Lymphoma
- 462. A method of claim 1, wherein said cancer is High-Risk Breast Cancer
- 463. A method of claim 1, wherein said cancer is Hindgut
- 464. A method of claim 1, wherein said cancer is Histiocytoma, Malignant
- 465. A method of claim 1, wherein said cancer is Histiocytosis
- 466. A method of claim 1, wherein said cancer is Hodgkin's Disease
- 467. A method of claim 1, wherein said cancer is Hodgkin's Disease in Pregnancy
- 468. A method of claim 1, wherein said cancer is Hormone-Refractory Prostate Cancer
- 469. A method of claim 1, wherein said cancer is Hypertrichosis lanuginosa acquisita (malignant down)
- 470. A method of claim 1, wherein said cancer is Hypertrophic Osteoarthropathy
- 471. A method of claim 1, wherein said cancer is In Situ Breast Cancer
- 472. A method of claim 1, wherein said cancer is Indolent MyelomaPleura Cancer
- 473. A method of claim 1, wherein said cancer is Infantile Fibromatosis
- 474. A method of claim 1, wherein said cancer is Infantile Fibrosarcoma
- 475. A method of claim 1, wherein said cancer is Inflammatory
- 476. A method of claim 1, wherein said cancer is Inflammatory Fibroid Polyps
- 477. A method of claim 1, wherein said cancer is Inflammatory Fibrosarcoma
- 478. A method of claim 1, wherein said cancer is Inflammatory Liposarcoma
- 479. A method of claim 1, wherein said cancer is Inflammatory Myofibroblasic Tumor

- 480. A method of claim 1, wherein said cancer is Insulinoma
- 481. A method of claim 1, wherein said cancer is Intermediate-Grade Lymphoma
- 482. A method of claim 1, wherein said cancer is Intraabdominal Fibromatosis
- 483. A method of claim 1, wherein said cancer is Intralobular Acinar Carcinoma
- 484. A method of claim 1, wherein said cancer is Intraocular Melanoma
- 485. A method of claim 1, wherein said cancer is Invasive Lobular Breast Cancer
- 486. A method of claim 1, wherein said cancer is Islet Cell Pancreatic Cancer
- 487. A method of claim 1, wherein said cancer is Kaposi's Sarcoma
- 488. A method of claim 1, wherein said cancer is Keratinizing
- 489. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Birt-Hogg-Dubé (BHD)
- 490. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Chromophobe Renal Carcinoma
- 491. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Clear Cell Renal Carcinoma
- 492. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC)
- 493. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Hereditary Papillary Renal Cell Carcinoma (HPRC)
- 494. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Onocytoma Renal Carcinoma
- 495. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Papillary Renal Carcinoma
- 496. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Papillary Renal Carcinoma, Type 1
- 497. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Papillary Renal Carcinoma, Type 2
- 498. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma) Von Hippel-Lindau (VHL) Clear Cell Renal Cell Carcinoma
- 499. A method of claim 1, wherein said cancer is Kidney Cancer (Renal Cell Carcinoma), Including:

- 500. A method of claim 1, wherein said cancer is Kidney Cancer with Lung Metastases
- 501. A method of claim 1, wherein said cancer is Krukenberg Tumor
- 502. A method of claim 1, wherein said cancer is Large Cell Calcifying
- 503. A method of claim 1, wherein said cancer is Large Cell Carcinoma Basaloid Carcinoma
- 504. A method of claim 1, wherein said cancer is Large Cell Carcinoma Clear Cell Carcinoma
- 505. A method of claim 1, wherein said cancer is Large Cell Carcinoma Combined Large Cell Neuroendocrine Carcinoma
- 506. A method of claim 1, wherein said cancer is Large Cell Carcinoma Large Cell Carcinoma with Rhabdoid Phenotype
- 507. A method of claim 1, wherein said cancer is Large Cell Carcinoma Large Cell Neuroendocrine Carcinoma
- 508. A method of claim 1, wherein said cancer is Large Cell Carcinoma Lymphoepitheliomalike Carcinoma
- 509. A method of claim 1, wherein said cancer is Large Cell Carcinoma:
- 510. A method of claim 1, wherein said cancer is Large Immature Cells
- 511. A method of claim 1, wherein said cancer is Large-Cell Lung Cancer
- 512. A method of claim 1, wherein said cancer is Large-Cell Lymphoma
- 513. A method of claim 1, wherein said cancer is Large-Cell, Diffuse Lymphoma
- 514. A method of claim 1, wherein said cancer is Larynx Cancer (Laryngeal Cancer)
- 515. A method of claim 1, wherein said cancer is Leiomyosarcoma
- 516. A method of claim 1, wherein said cancer is Leiomyosarcoma
- 517. A method of claim 1, wherein said cancer is Leiomyosarcoma
- 518. A method of claim 1, wherein said cancer is Leiomyosarcoma Foot
- 519. A method of claim 1, wherein said cancer is Leiomyosarcoma Pulmonary Artery
- 520. A method of claim 1, wherein said cancer is Leiomyosarcoma Uterus
- 521. A method of claim 1, wherein said cancer is Leiomyosarcoma Vena Cava
- 522. A method of claim 1, wherein said cancer is Leiomyosarcoma:
- 523. A method of claim 1, wherein said cancer is Leiomyosarcomas
- 524. A method of claim 1, wherein said cancer is Lentigo Maligna
- 525. A method of claim 1, wherein said cancer is Leukemia Acute
- 526. A method of claim 1, wherein said cancer is Leukemia Acute Lymphocytic (ALL)

- 527. A method of claim 1, wherein said cancer is Leukemia Acute Megakaryoblastic leukemia
- 528. A method of claim 1, wherein said cancer is Leukemia Acute Monocytic (AML)
- 529. A method of claim 1, wherein said cancer is Leukemia Acute Myelogenous (AML)
- 530. A method of claim 1, wherein said cancer is Leukemia Acute Myeloid (AML)
- 531. A method of claim 1, wherein said cancer is Leukemia Acute Promyelocytic (APL)
- 532. A method of claim 1, wherein said cancer is Leukemia B-Cell Chronic Lymphocytic Leukemia
- 533. A method of claim 1, wherein said cancer is Leukemia Chronic
- 534. A method of claim 1, wherein said cancer is Leukemia Chronic granulocytic leukemia
- 535. A method of claim 1, wherein said cancer is Leukemia Chronic Lymphocytic (CLL)
- 536. A method of claim 1, wherein said cancer is Leukemia Chronic Myelogenous
- 537. A method of claim 1, wherein said cancer is Leukemia Chronic Myeloid (CML)
- 538. A method of claim 1, wherein said cancer is Leukemia Chronic Myelomonocytic (CMML)
- 539. A method of claim 1, wherein said cancer is Leukemia CML, Philadelphia-Negative
- 540. A method of claim 1, wherein said cancer is Leukemia CMML
- 541. A method of claim 1, wherein said cancer is Leukemia Cutis
- 542. A method of claim 1, wherein said cancer is Leukemia Granulocytic
- 543. A method of claim 1, wherein said cancer is Leukemia Granulocytic Sarcomas and Chloromas (Leukemic tumors)
- 544. A method of claim 1, wherein said cancer is Leukemia Hairy Cell
- 545. A method of claim 1, wherein said cancer is Leukemia Infant Acute Megakaryoblastic Leukemia
- 546. A method of claim 1, wherein said cancer is Leukemia Large Granular Lymphocyte Leukemia
- 547. A method of claim 1, wherein said cancer is Leukemia Lymphoblastic
- 548. A method of claim 1, wherein said cancer is Leukemia Mature B-Cell Acute Lymphocytic Leukemia
- 549. A method of claim 1, wherein said cancer is Leukemia Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

- 550. A method of claim 1, wherein said cancer is Leukemia Precursor B-Lymphoblastic Leukemia
- 551. A method of claim 1, wherein said cancer is Leukemia Prolymphocytic
- 552. A method of claim 1, wherein said cancer is Leukemia Promyelocytic
- 553. A method of claim 1, wherein said cancer is Leukemia Secondary Myeloid Leukemia
- 554. A method of claim 1, wherein said cancer is Leukemia T-Cel
- 555. A method of claim 1, wherein said cancer is Leukemia:
- 556. A method of claim 1, wherein said cancer is Lichen Sclerosis
- 557. A method of claim 1, wherein said cancer is Li-Fraumeni syndrome
- 558. A method of claim 1, wherein said cancer is Limbic Encephalitis
- 559. A method of claim 1, wherein said cancer is Limited Stage Small Cell Lung Cancer
- 560. A method of claim 1, wherein said cancer is Linitis Plastica
- 561. A method of claim 1, wherein said cancer is Lip Cancer
- 562. A method of claim 1, wherein said cancer is Lipoma-like Liposarcoma
- 563. A method of claim 1, wherein said cancer is Lipomatous Tumors
- 564. A method of claim 1, wherein said cancer is Liposarcoma
- 565. A method of claim 1, wherein said cancer is Liver Cancer Angiosarcoma
- 566. A method of claim 1, wherein said cancer is Liver Cancer Cholangiocarcinoma (Bile Duct Cancer) Distal
- 567. A method of claim 1, wherein said cancer is Liver Cancer Cholangiocarcinoma (Bile Duct Cancer) Hilar (Klatskin's Tumors)
- 568. A method of claim 1, wherein said cancer is Liver Cancer Cholangiocarcinoma (Bile Duct Cancer) Intrahepatic
- 569. A method of claim 1, wherein said cancer is Liver Cancer Cholangiocarcinoma (Bile Duct Cancer).
- 570. A method of claim 1, wherein said cancer is Liver Cancer Cholangiocellular Carcinoma
- 571. A method of claim 1, wherein said cancer is Liver Cancer Emangioendotheliomas
- 572. A method of claim 1, wherein said cancer is Liver Cancer Epithelioid Hemangioendothelioma
- 573. A method of claim 1, wherein said cancer is Liver Cancer Fibrosarcoma
- 574. A method of claim 1, wherein said cancer is Liver Cancer Hemangioendothelioma

- 575. A method of claim 1, wherein said cancer is Liver Cancer Hemangiosarcoma
- 576. A method of claim 1, wherein said cancer is Liver Cancer Hepatic Cystadenocarcinoma
- 577. A method of claim 1, wherein said cancer is Liver Cancer Hepatoblastoma
- 578. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Carcinosarcoma
- 579. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Childhood
- 580. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Clear Cell
- 581. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Combined
- 582. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Fibrolamellar
- 583. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Giant Cell
- 584. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Sclerosing, Hepatoblastoma
- 585. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma) Spindle Cell
- 586. A method of claim 1, wherein said cancer is Liver Cancer Hepatocellular Carcinoma (Liver Cell Carcinoma):
- 587. A method of claim 1, wherein said cancer is Liver Cancer Histiocytoma
- 588. A method of claim 1, wherein said cancer is Liver Cancer Leiomyosarcoma
- 589. A method of claim 1, wherein said cancer is Liver Cancer Lymphoma
- 590. A method of claim 1, wherein said cancer is Liver Cancer Malignant Fibrous
- 591. A method of claim 1, wherein said cancer is Liver Cancer Malignant Schwannoma
- 592. A method of claim 1, wherein said cancer is Liver Cancer Mesenchymal sarcoma
- 593. A method of claim 1, wherein said cancer is Liver Cancer Metastases
- 594. A method of claim 1, wherein said cancer is Liver Cancer Mixed Hepatocellular Cholangiocarcinoma
- 595. A method of claim 1, wherein said cancer is Liver Cancer Osteosacoma

- 596. A method of claim 1, wherein said cancer is Liver Cancer Recurrent Liver Cancer
- 597. A method of claim 1, wherein said cancer is Liver Cancer Rhabdomyosarcoma
- 598. A method of claim 1, wherein said cancer is Liver Cancer Stage I
- 599. A method of claim 1, wherein said cancer is Liver Cancer Stage II
- 600. A method of claim 1, wherein said cancer is Liver Cancer Stage III
- 601. A method of claim 1, wherein said cancer is Liver Cancer Stage IV
- 602. A method of claim 1, wherein said cancer is Liver Cancer Undifferentiated Liver Cancer
- 603. A method of claim 1, wherein said cancer is Liver Cancer Including:
- 604. A method of claim 1, wherein said cancer is Lobular Carcinoma in Situ (LCIS)
- 605. A method of claim 1, wherein said cancer is Lobular Hyperplasia
- 606. A method of claim 1, wherein said cancer is localized fibrous mesothelioma
- 607. A method of claim 1, wherein said cancer is Low-Grade Lymphoma
- 608. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinoma
- 609. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Acinar
- 610. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Clear Cell Adenocarcinoma
- 611. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Mucinous (Colloid) Adenocarcinoma
- 612. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Mucinous Cystadenocarcinoma
- 613. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Papillary
- 614. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Signet-Ring Adenocarcinoma
- 615. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas Well-differentiated Fetal Adenocarcinoma
- 616. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas, Bronchioloalveolar Carcinoma
- 617. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas,

  Bronchioloalveolar Carcinoma, Mixed Mucinous and Nonmucinous/Indeterminate cell
  type

- 618. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas,
  Bronchioloalveolar Carcinoma, Mucinous (Goblet Cell) type
- 619. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas,

  Bronchioloalveolar Carcinoma, Nonmucinous (Clara Cell/type II Pneumocyte Type)
- 620. A method of claim 1, wherein said cancer is Lung Cancer Adenocarcinomas:
- 621. A method of claim 1, wherein said cancer is Lung Cancer Bronchioalveolar
- 622. A method of claim 1, wherein said cancer is Lung Cancer Cystic Mucinous
- 623. A method of claim 1, wherein said cancer is Lung Cancer Extrapulmonary Small Cell Anaplastic Carcinoma Extensive
- 624. A method of claim 1, wherein said cancer is Lung Cancer Extrapulmonary Small Cell
  Anaplastic Carcinoma Limited
- 625. A method of claim 1, wherein said cancer is Lung Cancer Germ Cell
- 626. A method of claim 1, wherein said cancer is Lung Cancer Giant Cell
- 627. A method of claim 1, wherein said cancer is Lung Cancer Large-Cell
- 628. A method of claim 1, wherein said cancer is Lung Cancer Mucinous
- 629. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer (NSCLC)
- 630. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Including:
- 631. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Recurrent
- 632. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Stage I
- 633. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Stage IIA
- 634. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Stage IIB
- 635. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Stage IIIA
- 636. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Stage IIIB

- 637. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer Stage IV
- 638. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer with Bone Metastases
- 639. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer with Brain Metastases
- 640. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer with Liver Metastases
- 641. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer with Lymph Node Metastases
- 642. A method of claim 1, wherein said cancer is Lung Cancer Non-Small Cell Lung Cancer with Skin Metastases
- 643. A method of claim 1, wherein said cancer is Lung Cancer Small Cell Combined small cell carcinoma
- 644. A method of claim 1, wherein said cancer is Lung Cancer Small Cell Extensive Stage
- 645. A method of claim 1, wherein said cancer is Lung Cancer Small Cell Limited Stage
- 646. A method of claim 1, wherein said cancer is Lung Cancer Small Cell Mixed small cell/large cell carcinoma
- 647. A method of claim 1, wherein said cancer is Lung Cancer Small Cell Pure small cell
- 648. A method of claim 1, wherein said cancer is Lung Cancer Small Cell with Brain Metastases
- 649. A method of claim 1, wherein said cancer is Lung Cancer with Adrenal Gland Metastases
- 650. A method of claim 1, wherein said cancer is Lung Cancer with Bone Metastases
- 651. A method of claim 1, wherein said cancer is Lung Cancer with Brain Metastases
- 652. A method of claim 1, wherein said cancer is Lung Cancer with Liver Metastases
- 653. A method of claim 1, wherein said cancer is Lung Cancer with Lymph Node Metastases
- 654. A method of claim 1, wherein said cancer is Lung Cancer with Ovarian Metastases
- 655. A method of claim 1, wherein said cancer is Lung Cancer with Skin Metastases
- 656. A method of claim 1, wherein said cancer is Lung Cancer, Recurrent
- 657. A method of claim 1, wherein said cancer is Lung Cancer, Small Cell:
- 658. A method of claim 1, wherein said cancer is Lung Cancer, Squamous

- 659. A method of claim 1, wherein said cancer is Lung Cancer, Squamous Dysplasia/Carcinoma in situ
- 660. A method of claim 1, wherein said cancer is Lung Cancer, Stage I
- 661. A method of claim 1, wherein said cancer is Lung Cancer, Stage II
- 662. A method of claim 1, wherein said cancer is Lung Cancer, Stage III
- 663. A method of claim 1, wherein said cancer is Lung Cancer, Stage IIIA
- 664. A method of claim 1, wherein said cancer is Lung Cancer, Stage IIIB
- 665. A method of claim 1, wherein said cancer is Lung Cancer, Stage IV
- 666. A method of claim 1, wherein said cancer is Lung Cancer, Superior Sulcus Tumors (Pancoast tumors)
- 667. A method of claim 1, wherein said cancer is Lung Cancer, Unclassified
- 668. A method of claim 1, wherein said cancer is Lung Cancer:
- 669. A method of claim 1, wherein said cancer is Lung Metastases
- 670. A method of claim 1, wherein said cancer is Lymph Node Excision
- 671. A method of claim 1, wherein said cancer is Lymph Node Metastases
- 672. A method of claim 1, wherein said cancer is Lymphangiosarcoma
- 673. A method of claim 1, wherein said cancer is Lymphangitic Metastasis
- 674. A method of claim 1, wherein said cancer is Lymphoblastic Leukemia
- 675. A method of claim 1, wherein said cancer is Lymphoblastic Lymphoma
- 676. A method of claim 1, wherein said cancer is Lymphocytic Lymphoma
- 677. A method of claim 1, wherein said cancer is Lymphoepithelioma-like Carcinoma
- 678. A method of claim 1, wherein said cancer is Lymphoma
- 679. A method of claim 1, wherein said cancer is Lymphoma AIDS Related
- 680. A method of claim 1, wherein said cancer is Lymphoma Anaplastic
- 681. A method of claim 1, wherein said cancer is Lymphoma Anaplastic Large Cell (ALCL)
- 682. A method of claim 1, wherein said cancer is Lymphoma B-Cell
- 683. A method of claim 1, wherein said cancer is Lymphoma B-Cell Large Diffuse
- 684. A method of claim 1, wherein said cancer is Lymphoma B-Cell Large- Lymphomatoid Granulomatosis Type
- 685. A method of claim 1, wherein said cancer is Lymphoma B-Cell Monocytoid
- 686. A method of claim 1, wherein said cancer is Lymphoma Breast

- 687. A method of claim 1, wherein said cancer is Lymphoma CD30+ Large T-cell Lymphoma
- 688. A method of claim 1, wherein said cancer is Lymphoma CD56+ Nasal-Type NK/T-Cell Lymphoma
- 689. A method of claim 1, wherein said cancer is Lymphoma Central Nervous System
- 690. A method of claim 1, wherein said cancer is Lymphoma Cutaneous T-Cell Mycosis Fungoides, Agetoid Reticulosis or Woringer-Kolopp disease
- 691. A method of claim 1, wherein said cancer is Lymphoma Cutaneous T-Cell:
- 692. A method of claim 1, wherein said cancer is Lymphoma Diffuse
- 693. A method of claim 1, wherein said cancer is Lymphoma Diffuse, Large-Cell
- 694. A method of claim 1, wherein said cancer is Lymphoma Enteropathy-Type T-Cell Lymphoma
- 695. A method of claim 1, wherein said cancer is Lymphoma Eye
- 696. A method of claim 1, wherein said cancer is Lymphoma Follicular
- 697. A method of claim 1, wherein said cancer is Lymphoma Follicular, Small-Cleaved Cell
- 698. A method of claim 1, wherein said cancer is Lymphoma Gastrointestinal
- 699. A method of claim 1, wherein said cancer is Lymphoma Granular, Lymphocytic
- 700. A method of claim 1, wherein said cancer is Lymphoma Granulomatous slack skin Cutaneous
- 701. A method of claim 1, wherein said cancer is Lymphoma Granulomatous slack skin Lymphomatoid
- 702. A method of claim 1, wherein said cancer is Lymphoma Granulomatous slack skin Papulosis
- 703. A method of claim 1, wherein said cancer is Lymphoma Granulomatous slack skin Primary
- 704. A method of claim 1, wherein said cancer is Lymphoma Hepatosplenic T-Cell Lymphoma
- 705. A method of claim 1, wherein said cancer is Lymphoma High-Grade
- 706. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's Disease Granuloma
- 707. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease Lymphocyte-Depleted Hodgkin's Lymphoma
- 708. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease Lymphocyte-Predominant Hodgkin's Lymphoma

- 709. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease Lymphocyte-Rich Classic Hodgkin's Lymphoma
- 710. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease Mixed-Cellularity Hodgkin's Lymphoma
- 711. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's Disease Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
- 712. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's Disease Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
- 713. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease Nodular Sclerosis Hodgkin's Lymphoma
- 714. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's Disease Paragranuloma
- 715. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's Disease Sarcoma
- 716. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease, Intravascular Large B-Cell Lymphoma
- 717. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease, Low-Grade B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue
- 718. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's disease, Lymphoplasmacytic lymphoma
- 719. A method of claim 1, wherein said cancer is Lymphoma Hodgkin's Disease:
- 720. A method of claim 1, wherein said cancer is Lymphoma Intermediate Grade
- 721. A method of claim 1, wherein said cancer is Lymphoma Large-Cell
- 722. A method of claim 1, wherein said cancer is Lymphoma Large-Cell, Diffuse
- 723. A method of claim 1, wherein said cancer is Lymphoma Low-Grade
- 724. A method of claim 1, wherein said cancer is Lymphoma Lymphoblastic Lymphoma
- 725. A method of claim 1, wherein said cancer is Lymphoma Lymphocytic Lymphoma
- 726. A method of claim 1, wherein said cancer is Lymphoma Lymphocytic, Large Granular
- 727. A method of claim 1, wherein said cancer is Lymphoma Lymphocytic, Small
- 728. A method of claim 1, wherein said cancer is Lymphoma MALT
- 729. A method of claim 1, wherein said cancer is Lymphoma Mantle Cell

- 730. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Burkitt's & Atypical Burkitt's
- 731. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Cutaneous T-cell
- 732. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Diffuse
- 733. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's High Grade
- 734. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Immunoblastic Diffuse
- 735. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Intermediate Grade
- 736. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Intermediately Differentiated Diffuse
- 737. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Large Cell Follicular
- 738. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Low Grade
- 739. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Mixed Cell Diffuse
- 740. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Mixed Follicular
- 741. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Non-Burkitt's
- 742. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Small Cleaved Cell Diffuse,
- 743. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Small Cleaved Cell Follicular
- 744. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's Small Lymphocytic
- 745. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's T-Cell, Cutaneous
- 746. A method of claim 1, wherein said cancer is Lymphoma Non-Hodgkin's, Including:
- 747. A method of claim 1, wherein said cancer is Lymphoma, Granulomatous slack skin:
- 748. A method of claim 1, wherein said cancer is Lymphoma, Orbital

- 749. A method of claim 1, wherein said cancer is Lymphoma, Peripheral T-Cell
- 750. A method of claim 1, wherein said cancer is Lymphoma, Primary Central Nervous System
- 751. A method of claim 1, wherein said cancer is Lymphoma, Small Cleaved Cell
- 752. A method of claim 1, wherein said cancer is Lymphoma, Soft tissue
- 753. A method of claim 1, wherein said cancer is Lymphoma, T-Cell
- 754. A method of claim 1, wherein said cancer is Lymphoma, T-Cell, Cutaneous
- 755. A method of claim 1, wherein said cancer is Lymphoma, Thyroid
- 756. A method of claim 1, wherein said cancer is Lymphoma:
- 757. A method of claim 1, wherein said cancer is Malignant Ascites
- 758. A method of claim 1, wherein said cancer is Malignant Carcinoid Syndrome Atypical
- 759. A method of claim 1, wherein said cancer is Malignant Carcinoid Syndrome Typical
- 760. A method of claim 1, wherein said cancer is Malignant Carcinoid Syndrome:
- 761. A method of claim 1, wherein said cancer is Malignant Extrarenal Rhabdoid Tumor
- 762. A method of claim 1, wherein said cancer is Malignant Fibrous Histiocytoma
- 763. A method of claim 1, wherein said cancer is Malignant Fibrous Histiocytoma
- 764. A method of claim 1, wherein said cancer is Malignant Fibrous Histiocytoma
- 765. A method of claim 1, wherein said cancer is Malignant Giant Cell Tumor of Tendon Sheath
- 766. A method of claim 1, wherein said cancer is Malignant Glomus Tumor (Glomangiosarcoma)
- 767. A method of claim 1, wherein said cancer is Malignant Hemangiopericytoma
- 768. A method of claim 1, wherein said cancer is Malignant Hemangiopericytoma
- 769. A method of claim 1, wherein said cancer is Malignant Melanoma
- 770. A method of claim 1, wherein said cancer is Malignant Mesenchymal Tmors
- 771. A method of claim 1, wherein said cancer is Malignant Mesenchymoma
- 772. A method of claim 1, wherein said cancer is Malignant Mixed Mullerian Tumor
- 773. A method of claim 1, wherein said cancer is Malignant Peripheral Nerve Sheath Tumor
- 774. A method of claim 1, wherein said cancer is Malignant Peripheral Nerve Sheath Tumor (MPNST)
- 775. A method of claim 1, wherein said cancer is Malignant Pleural Effusion
- 776. A method of claim 1, wherein said cancer is Malignant Pleural Mesothelioma
- 777. A method of claim 1, wherein said cancer is Malignant Schwannoma

- 778. A method of claim 1, wherein said cancer is Malignant Triton Tumor
- 779. A method of claim 1, wherein said cancer is MALT Lymphoma
- 780. A method of claim 1, wherein said cancer is Mantle Cell Lymphoma
- 781. A method of claim 1, wherein said cancer is Mature
- 782. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Chemodectoma (Paraganglioma)
- 783. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Choriocarcinoma
- 784. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Endodermal Sinus Tumors (Yolk Sac Tumors)
- 785. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Fibroelastoma
- 786. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Fibroma
- 787. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Fibrosarcoma
- 788. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Ganglioneuroblastoma
- 789. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Ganglioneuroma
- 790. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Granular Cell Myoblastomas
- 791. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Hemangioendothelioma
- 792. A method of claim 1, wherein said cancer is Mediastinal Neoplasms Hemangioma
- 793. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Histiocytic Lymphoma
- 794. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Immature Teratomas
- 795. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, including:
- 796. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Leiomyoma
- 797. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Leiomyosarcoma
- 798. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Lipoma
- 799. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Liposarcoma
- 800. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Lymphangioma
- 801. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Lymphangiomyoma

- 802. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Malignant Fibrous Histiocytoma
- 803. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Mesenchymoma
- 804. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma,
- 805. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Endodermal Sinus Elements
- 806. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Seminomatous Elements
- 807. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Tetroid Elements
- 808. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Mixed Embryonal Cell Carcinoma, with Trophoblastic Elements
- 809. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Myxoma
- 810. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Neuroblastoma
- 811. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Neurofibroma
- 812. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Neuroilemoma (schwannoma)
- 813. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Neurosarcoma
- 814. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Nonseminomatous
- 815. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Permeative Neuroectodermal Tumor
- 816. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Pheochromocytoma
- 817. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Pure Embryonal Cell Carcinoma
- 818. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Rhabdomyosarcoma
- 819. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Seminoma
- 820. A method of claim 1, wherein said cancer is Mediastinal Neoplasms, Xanthogranuloma
- 821. A method of claim 1, wherein said cancer is Medulary Thyroid Carcinoma
- 822. A method of claim 1, wherein said cancer is Medullary
- 823. A method of claim 1, wherein said cancer is Medullary thyroid carcinoma (MTC)

- 824. A method of claim 1, wherein said cancer is Medulloblastoma
- 825. A method of claim 1, wherein said cancer is Melanoma
- 826. A method of claim 1, wherein said cancer is Melanomas including:
- 827. A method of claim 1, wherein said cancer is Melanomas, Amelanotic melanoma
- 828. A method of claim 1, wherein said cancer is Melanomas, Cutaneous
- 829. A method of claim 1, wherein said cancer is Melanomas, Extraocular Extension
- 830. A method of claim 1, wherein said cancer is Melanomas, Intraocular
- 831. A method of claim 1, wherein said cancer is Melanomas, Melanoma-associated retinopathy
- 832. A method of claim 1, wherein said cancer is Melanomas, Multiple Choroidal Malignant Melanoma
- 833. A method of claim 1, wherein said cancer is Melanomas, Soft Tissue
- 834. A method of claim 1, wherein said cancer is Melanomas, Uveal-spindle cell (A, B, or both), mixed cell, epithelioid cell
- 835. A method of claim 1, wherein said cancer is Melanomas, with Brain Metastases
- 836. A method of claim 1, wherein said cancer is Melanomas, with Liver Metastases
- 837. A method of claim 1, wherein said cancer is Melanomas, with Lung Metastases
- 838. A method of claim 1, wherein said cancer is Melanosis
- 839. A method of claim 1, wherein said cancer is Meningeal Cancer
- 840. A method of claim 1, wherein said cancer is Meningeal Metastases
- 841. A method of claim 1, wherein said cancer is Meningioma
- 842. A method of claim 1, wherein said cancer is Merkel Cell
- 843. A method of claim 1, wherein said cancer is Merkel Cell Carcinoma
- 844. A method of claim 1, wherein said cancer is Merkel Cell Skin Cancer
- 845. A method of claim 1, wherein said cancer is Mesenchymal Chondrosarcoma
- 846. A method of claim 1, wherein said cancer is Mesenchymal Chondrosarcoma
- 847. A method of claim 1, wherein said cancer is Mesenteric Fibromatosis
- 848. A method of claim 1, wherein said cancer is Mesothelioma, Biphasic
- 849. A method of claim 1, wherein said cancer is Mesothelioma, Epithelial
- 850. A method of claim 1, wherein said cancer is Mesothelioma, Poorly Differentiated
- 851. A method of claim 1, wherein said cancer is Mesothelioma, Sarcomatoid
- 852. A method of claim 1, wherein said cancer is Mesothelioma:

- 853. A method of claim 1, wherein said cancer is Metastatic carcinoma of unknown primary site, Metastatic gestational Choriocarcinoma
- 854. A method of claim 1, wherein said cancer is Metastatic carcinoma of unknown primary site, poorly differentiated carcinoma (with or without features of adenocarcinoma
- 855. A method of claim 1, wherein said cancer is Metastatic carcinoma of unknown primary site, poorly differentiated neoplasm
- 856. A method of claim 1, wherein said cancer is Metastatic carcinoma of unknown primary site, well-differentiated and moderately well-differentiated adenocarcinoma
- 857. A method of claim 1, wherein said cancer is Metastatic carcinoma of unknown primary site:
- 858. A method of claim 1, wherein said cancer is Metastatic Melanoma
- 859. A method of claim 1, wherein said cancer is Metastatic Neuroblastoma
- 860. A method of claim 1, wherein said cancer is Metastatic Undifferentiated Carcinoma
- 861. A method of claim 1, wherein said cancer is Microcystic adrexal carcinoma
- 862. A method of claim 1, wherein said cancer is Midgut
- 863. A method of claim 1, wherein said cancer is Mixed
- 864. A method of claim 1, wherein said cancer is mixed (elements of both epithelial and sarcomatoid
- 865. A method of claim 1, wherein said cancer is Mixed Mullerian Tumor
- 866. A method of claim 1, wherein said cancer is monoclonal gammopathy of unknown significance (MGUS)
- 867. A method of claim 1, wherein said cancer is Monophasic Synovial Sarcoma
- 868. A method of claim 1, wherein said cancer is Mucinous
- 869. A method of claim 1, wherein said cancer is mucinous adenocarcinoma of the appendix and colon
- 870. A method of claim 1, wherein said cancer is Mucinous Carcinoma
- 871. A method of claim 1, wherein said cancer is Mucinous Carcinoma
- 872. A method of claim 1, wherein said cancer is Mucoepidermoid carcinoma
- 873. A method of claim 1, wherein said cancer is Mucoepidermoid Carcinoma
- 874. A method of claim 1, wherein said cancer is Mucosal-Associated Lymphoid Tissue Lymphoma
- 875. A method of claim 1, wherein said cancer is Muir-Torre syndrome

- 876. A method of claim 1, wherein said cancer is Multicentric reticulohistiocytosis
- 877. A method of claim 1, wherein said cancer is multicystic and well-differentiated papillary peritoneal mesotheliomas
- 878. A method of claim 1, wherein said cancer is Multiple Focal Peritoneal Papillary Carcinoma
- 879. A method of claim 1, wherein said cancer is Multiple Myeloma
- 880. A method of claim 1, wherein said cancer is multiple myeloma (MM)
- 881. A method of claim 1, wherein said cancer is Muscle-Invasive Bladder Tumor
- 882. A method of claim 1, wherein said cancer is Mycosis Fungoides
- 883. A method of claim 1, wherein said cancer is Myeloblastomas (chloromas or granulocytic sarcomas)
- 884. A method of claim 1, wherein said cancer is Myelodysplasia
- 885. A method of claim 1, wherein said cancer is Myelodysplastic Syndrome
- 886. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), 5q-syndrome
- 887. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), hypocellular MDS
- 888. A method of claim 1, wherein said cancer is Myelodysplastic Syndromes (MDS), hypoplastic
- 889. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), preleukemia, or smoldering leukemia
- 890. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), refractory anemia (RA),
- 891. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), unclassifiable MDS
- 892. A method of claim 1, wherein said cancer is Myelodysplastic Syndromes (MDS), with Eosinophilia or Basophilia
- 893. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), with extensive fibrosis
- 894. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS), with Myelofibrosis
- 895. A method of claim 1, wherein said cancer is Myelodysplastic syndromes (MDS):

- 896. A method of claim 1, wherein said cancer is Myeloma, Bence-Jones
- 897. A method of claim 1, wherein said cancer is Myeloproliferative Disorder
- 898. A method of claim 1, wherein said cancer is Myofibroblastic Tumor
- 899. A method of claim 1, wherein said cancer is Myosarcoma
- 900. A method of claim 1, wherein said cancer is Myxoid
- 901. A method of claim 1, wherein said cancer is Myxoid (Round Cell) Liposarcoma
- 902. A method of claim 1, wherein said cancer is Myxoid Chondrosarcoma
- 903. A method of claim 1, wherein said cancer is Nail/Nail Bed Cancer
- 904. A method of claim 1, wherein said cancer is Nasal Cavity Cancer
- 905. A method of claim 1, wherein said cancer is Nasopharynx Cancer
- 906. A method of claim 1, wherein said cancer is Neck, Radical Dissection
- 907. A method of claim 1, wherein said cancer is Necrolytic migratory erythema
- 908. A method of claim 1, wherein said cancer is Neoplastic Meningitis
- 909. A method of claim 1, wherein said cancer is Nerve Sheath Tumors
- 910. A method of claim 1, wherein said cancer is Neural Tumors
- 911. A method of claim 1, wherein said cancer is Neuroblastoma (Adult)
- 912. A method of claim 1, wherein said cancer is Neuroblastoma (Child)
- 913. A method of claim 1, wherein said cancer is Neuroendocrine Tumors, Carcinoids (Foregut, Hindgut, Midgut)
- 914. A method of claim 1, wherein said cancer is Neuroendocrine Tumors, Glandular
- 915. A method of claim 1, wherein said cancer is Neuroendocrine Tumors, Insular
- 916. A method of claim 1, wherein said cancer is Neuroendocrine Tumors, Mixed
- 917. A method of claim 1, wherein said cancer is Neuroendocrine Tumors, Trabecular
- 918. A method of claim 1, wherein said cancer is Neuroendocrine Tumors, Undifferentiated
- 919. A method of claim 1, wherein said cancer is Neuroendocrine Tumors:
- 920. A method of claim 1, wherein said cancer is Neurofibromatosis Type I (Von Reckling-Hausen's Disease)
- 921. A method of claim 1, wherein said cancer is Neurofibrosarcoma
- 922. A method of claim 1, wherein said cancer is Neurofibrosarcoma
- 923. A method of claim 1, wherein said cancer is Neurologic Paraneoplastic Syndrome
- 924. A method of claim 1, wherein said cancer is Neuromuscular Junction Disorders

- 925. A method of claim 1, wherein said cancer is Nonkeratinizing
- 926. A method of claim 1, wherein said cancer is Non-melanoma skin cancer
- 927. A method of claim 1, wherein said cancer is Nose Tumor
- 928. A method of claim 1, wherein said cancer is Ocular Melanoma
- 929. A method of claim 1, wherein said cancer is Olfactory Cancer
- 930. A method of claim 1, wherein said cancer is Oligodendroglioma
- 931. A method of claim 1, wherein said cancer is Optic Glioma
- 932. A method of claim 1, wherein said cancer is Oral Cancer
- 933. A method of claim 1, wherein said cancer is Orbital Lymphoma
- 934. A method of claim 1, wherein said cancer is Oropharynx Cancer
- 935. A method of claim 1, wherein said cancer is Osteochondroma
- 936. A method of claim 1, wherein said cancer is Osteogenic Sarcoma
- 937. A method of claim 1, wherein said cancer is Osteoid Tumors
- 938. A method of claim 1, wherein said cancer is Osteomyelitis
- 939. A method of claim 1, wherein said cancer is Osteosarcoma
- 940. A method of claim 1, wherein said cancer is Osteosarcoma, Central Medullary
- 941. A method of claim 1, wherein said cancer is Osteosarcoma, Low-Grade Intraosseous
- 942. A method of claim 1, wherein said cancer is Osteosarcoma, Paget's Sarcoma
- 943. A method of claim 1, wherein said cancer is Osteosarcoma, Parosteal
- 944. A method of claim 1, wherein said cancer is Osteosarcoma, Periosteal
- 945. A method of claim 1, wherein said cancer is Osteosarcoma, Small Cell
- 946. A method of claim 1, wherein said cancer is Osteosarcoma:
- 947. A method of claim 1, wherein said cancer is Ovarian Cancer (Adult)
- 948. A method of claim 1, wherein said cancer is Ovarian Cancer (Child)
- 949. A method of claim 1, wherein said cancer is Ovarian Cancer with Bone Metastases
- 950. A method of claim 1, wherein said cancer is Ovarian Cancer with Liver Metastases
- 951. A method of claim 1, wherein said cancer is Ovarian Cancer with Lung Metastases
- 952. A method of claim 1, wherein said cancer is Ovarian Cancer with Meningeal Metastases
- 953. A method of claim 1, wherein said cancer is Ovarian Cancer with Pleural Effusion
- 954. A method of claim 1, wherein said cancer is Ovarian Cancer with Spleen Metastases
- 955. A method of claim 1, wherein said cancer is Ovarian Cancer, Advanced

- 956. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Gynandroblastoma
- 957. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Hilus Cell Tumor
- 958. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Leydig Cell Tumor
- 959. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Sertolid Cell Tumor (Tubular Adenoma of Pick)
- 960. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Sertoli-Leydig Cell Tumor
- 961. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Tubular Androblastoma
- 962. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma, Unclassified
- 963. A method of claim 1, wherein said cancer is Ovarian Cancer, Androblastoma:
- 964. A method of claim 1, wherein said cancer is Ovarian Cancer, Borderline, Endometrioid
- 965. A method of claim 1, wherein said cancer is Ovarian Cancer, Borderline, Mucinous,
- 966. A method of claim 1, wherein said cancer is Ovarian Cancer, Borderline, Mucinous, Micropapillary Serous Carcinoma
- 967. A method of claim 1, wherein said cancer is Ovarian Cancer, Borderline, Mucinous, Pseudomyxoma Peritonei Serous
- 968. A method of claim 1, wherein said cancer is Ovarian Cancer, Borderline:
- 969. A method of claim 1, wherein said cancer is Ovarian Cancer, Carcinosarcoma
- 970. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Brenner Tumor
- 971. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Carcinoma
- 972. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Carcinoma, Adenoacanthoma
- 973. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Carcinoma, Adenocarcinoma

- 974. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Carcinoma, Cystadenofibroma
- 975. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Carcinoma, Malignant Adenofibroma,
- 976. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Carcinoma, Malignant Adenofibroma,
- 977. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Clear Cell (mesonephroid) Tumor,
- 978. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Clear Cell (mesonephroid) Tumor, Adenocarcinoma
- 979. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Clear Cell (mesonephroid) Tumor, Carcinoma
- 980. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Endometrioid Stromal Sarcoma
- 981. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Mesodermal (Mullerian) Mixed Tumor,
- 982. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Mesodermal (Mullerian) Mixed Tumor, Heterologous
- 983. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Mesodermal (Mullerian) Mixed Tumor, Homologous
- 984. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Mixed Epithelial Tumor
- 985. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Unclassified
- 986. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor, Undifferentiated Carcinoma
- 987. A method of claim 1, wherein said cancer is Ovarian Cancer, Endometrioid Tumor:
- 988. A method of claim 1, wherein said cancer is Ovarian Cancer, Epithelial
- 989. A method of claim 1, wherein said cancer is Ovarian Cancer, Germ Cell, Dysgerminoma
- 990. A method of claim 1, wherein said cancer is Ovarian Cancer, Germ Cell, Embryonal Carcinoma

- 991. A method of claim 1, wherein said cancer is Ovarian Cancer, Germ Cell, Endodermal Sinus Tumor
- 992. A method of claim 1, wherein said cancer is Ovarian Cancer, Germ Cell, Polyembryoma
- 993. A method of claim 1, wherein said cancer is Ovarian Cancer, Germ Cell:
- 994. A method of claim 1, wherein said cancer is Ovarian Cancer, Gonadoblastoma, Mixed
- 995. A method of claim 1, wherein said cancer is Ovarian Cancer, Gonadoblastoma, Pure
- 996. A method of claim 1, wherein said cancer is Ovarian Cancer, Gonadoblastoma:
- 997. A method of claim 1, wherein said cancer is Ovarian Cancer, Granulosa-Stromal Cell Tumor, Fibroma
- 998. A method of claim 1, wherein said cancer is Ovarian Cancer, Granulosa-Stromal Cell Tumor, Granulosa Cell Tumor
- 999. A method of claim 1, wherein said cancer is Ovarian Cancer, Granulosa-Stromal Cell Tumor, Thecoma-Fibroma Tumor
- 1000. A method of claim 1, wherein said cancer is Ovarian Cancer, Granulosa-Stromal Cell Tumor, Unclassified
- 1001. A method of claim 1, wherein said cancer is Ovarian Cancer, Granulosa-Stromal Cell Tumor:
- 1002. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Choriocarcinoma
- 1003. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Mixed
- 1004. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Teratoma,
- 1005. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Carcinoid
- 1006. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Immature
- 1007. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Mature Dermoid Cyst with Malignant Transformation
- 1008. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor,
  Teratoma, Monodermal

- 1009. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Struma Ovarii
- 1010. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor, Teratoma, Struma Ovarii and Carcinoid
- 1011. A method of claim 1, wherein said cancer is Ovarian Cancer, Lipoid Cell Tumor:
- 1012. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Mucinous Tumor, Adenocarcinoma
- 1013. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Mucinous Tumor, Adenocarcinoma Cystadenocarcinoma
- 1014. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Mucinous Tumor, Malignant Adenofibroma
- 1015. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Mucinous Tumor, Malignant Adenofibroma Cystadenofibroma
- 1016. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Mucinous Tumor:
- 1017. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor, Adenocarcinoma,
- 1018. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor, Adenocarcinoma, Papillary Adenocarcinoma
- 1019. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor, Adenocarcinoma, Papillary Cystadenocarcinoma
- 1020. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor, Malignant Adenofibroma,
- 1021. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor, Malignant Adenofibroma, Cystadenofibroma
- 1022. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor, Surface Papillary Carcinoma
- 1023. A method of claim 1, wherein said cancer is Ovarian Cancer, Malignant Serous Tumor:
- 1024. A method of claim 1, wherein said cancer is Ovarian Cancer, Peritoneal
- 1025. A method of claim 1, wherein said cancer is Ovarian Cancer, Recurrent
- 1026. A method of claim 1, wherein said cancer is Ovarian Cancer, Sarcoma

- 1027. A method of claim 1, wherein said cancer is Ovarian Cancer, Stage I
- 1028. A method of claim 1, wherein said cancer is Ovarian Cancer, Stage II
- 1029. A method of claim 1, wherein said cancer is Ovarian Cancer, Stage III
- 1030. A method of claim 1, wherein said cancer is Ovarian Cancer, Stage IV
- 1031. A method of claim 1, wherein said cancer is Ovarian Cancer, Stromal Cell
- 1032. A method of claim 1, wherein said cancer is Pachydermoperiostosis
- 1033. A method of claim 1, wherein said cancer is Paget's Disease of the Breast
- 1034. A method of claim 1, wherein said cancer is Paget's disease of the breast Pancreatic Cancer, Islet Cell
- 1035. A method of claim 1, wherein said cancer is Paget's Lesions
- 1036. A method of claim 1, wherein said cancer is Palmar
- 1037. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Adenosquamous
- 1038. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Anaplastic
- 1039. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Colloid Ductal (mucinous noncystics)
- 1040. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Ductal Adenocarcinoma
- 1041. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Medullary
- 1042. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Signet-ring Cell
- 1043. A method of claim 1, wherein said cancer is Pancreatic Cancer Adenocarcinoma, Undifferentiated carcinoma with osteoclast-like giant cells
- 1044. A method of claim 1, wherein said cancer is Pancreatic Cancer Operable
- 1045. A method of claim 1, wherein said cancer is Pancreatic Cancer Pancreatic endocrine tumors (PET)
- 1046. A method of claim 1, wherein said cancer is Pancreatic Cancer Pancreatoblastoma
- 1047. A method of claim 1, wherein said cancer is Pancreatic Cancer PPoma
- 1048. A method of claim 1, wherein said cancer is Pancreatic Cancer Stage I

- 1049. A method of claim 1, wherein said cancer is Pancreatic Cancer Stage II
- 1050. A method of claim 1, wherein said cancer is Pancreatic Cancer Stage III
- 1051. A method of claim 1, wherein said cancer is Pancreatic Cancer Stage IVA
- 1052. A method of claim 1, wherein said cancer is Pancreatic Cancer Stage IVB
- 1053. A method of claim 1, wherein said cancer is Pancreatic Cancer VIPoma
- 1054. A method of claim 1, wherein said cancer is Pancreatic Cancer- Carcinoid
- 1055. A method of claim 1, wherein said cancer is Pancreatic Cancer including:
- 1056. A method of claim 1, wherein said cancer is Pancreatic Cancer with Liver Metastases
- 1057. A method of claim 1, wherein said cancer is Pancreatic Cancer, Acinar cell carcinoma
- 1058. A method of claim 1, wherein said cancer is Pancreatic Cancer, Adenocarcinoma:
- 1059. A method of claim 1, wherein said cancer is Pancreatic Cancer, Borderline Pancreatic Tumors
- 1060. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Intraductal Papillary Mucinous Neoplasms
- 1061. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms
- 1062. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms Borderline
- 1063. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms Cystadenocarcinoma
- 1064. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms Cystadenoma
- 1065. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Mucinous Cystic Neoplasms Mucinous Cystic Neoplasm with In Situ Carcinoma
- 1066. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms, Serous Cyctic Neoplasms
- 1067. A method of claim 1, wherein said cancer is Pancreatic Cancer, Cystic Neoplasms:
- 1068. A method of claim 1, wherein said cancer is Pancreatic Cancer, Inoperable
- 1069. A method of claim 1, wherein said cancer is Pancreatic Cancer, Islet Cell
- 1070. A method of claim 1, wherein said cancer is Pancreatic Cancer, Islet cell tumors, gastrinoma

- 1071. A method of claim 1, wherein said cancer is Pancreatic Cancer, Islet Cell, gastrinoma
- 1072. A method of claim 1, wherein said cancer is Pancreatic Cancer, Islet Cell, insulinoma
- 1073. A method of claim 1, wherein said cancer is Pancreatic Cancer, Islet Cell, lucagonoma
- 1074. A method of claim 1, wherein said cancer is Pancreatic Cancer, Recurrent Pancreactic Cancer
- 1075. A method of claim 1, wherein said cancer is Papillary
- 1076. A method of claim 1, wherein said cancer is Papillary Serous Carcinoma of the Peritoneum
- 1077. A method of claim 1, wherein said cancer is Papillary thyroid cancer without oxyphilia
- 1078. A method of claim 1, wherein said cancer is Papillary thyroid carcinoma with papillary renal neoplasia (PTC-RCC)
- 1079. A method of claim 1, wherein said cancer is Paraganglioma
- 1080. A method of claim 1, wherein said cancer is Paranasal Sinus Cancer
- 1081. A method of claim 1, wherein said cancer is paraneoplastic encephalomyelitis
- 1082. A method of claim 1, wherein said cancer is Paraneoplastic Motor Neuron Disorders
- 1083. A method of claim 1, wherein said cancer is Paraneoplastic neuromyotonia
- 1084. A method of claim 1, wherein said cancer is Paraneoplastic parkinsonian syndromes
- 1085. A method of claim 1, wherein said cancer is Paraneoplastic pemphigus
- 1086. A method of claim 1, wherein said cancer is Paraneoplastic Peripheral Neuropathies
- 1087. A method of claim 1, wherein said cancer is Paraneoplastic Syndromes
- 1088. A method of claim 1, wherein said cancer is Paraneoplastic Vision Loss
- 1089. A method of claim 1, wherein said cancer is Parathyroid carcinoma
- 1090. A method of claim 1, wherein said cancer is Parathyroid neoplasia
- 1091. A method of claim 1, wherein said cancer is Parotid Gland Cancer
- 1092. A method of claim 1, wherein said cancer is Pelvic Tumor
- 1093. A method of claim 1, wherein said cancer is Penile (Peyronie's Fibromatosis)
- 1094. A method of claim 1, wherein said cancer is Penis Cancer Advanced Penile Cancer
- 1095. A method of claim 1, wherein said cancer is Penis Cancer Balantitis Xerotica Obliterans
- 1096. A method of claim 1, wherein said cancer is Penis Cancer Buschke-Löwenstein Tumor
- 1097. A method of claim 1, wherein said cancer is Penis Cancer Carcinoma In Situ
- 1098. A method of claim 1, wherein said cancer is Penis Cancer Invasive Penile Cancer

- 1099. A method of claim 1, wherein said cancer is Penis Cancer Penile Verrucous Carcinoma
- 1100. A method of claim 1, wherein said cancer is Penis Cancer:
- 1101. A method of claim 1, wherein said cancer is Periampullary Cancer
- 1102. A method of claim 1, wherein said cancer is Pericardial Effusion:
- 1103. A method of claim 1, wherein said cancer is Pericardial Mesothelioma
- 1104. A method of claim 1, wherein said cancer is Peripheral Nerve Sheath Tumor
- 1105. A method of claim 1, wherein said cancer is Peripheral T-Cell Lymphoma
- 1106. A method of claim 1, wherein said cancer is Peritoneal cancer:
- 1107. A method of claim 1, wherein said cancer is Peritoneal Carcinomatosis:
- 1108. A method of claim 1, wherein said cancer is Peutz-Jeghers syndrome
- 1109. A method of claim 1, wherein said cancer is Pheochromocytoma
- 1110. A method of claim 1, wherein said cancer is Pinealoma
- 1111. A method of claim 1, wherein said cancer is Pineoblastoma
- 1112. A method of claim 1, wherein said cancer is Placental-Site Trophoblastic Tumors
- 1113. A method of claim 1, wherein said cancer is plasma cell leukemia
- 1114. A method of claim 1, wherein said cancer is plasma cell myeloma
- 1115. A method of claim 1, wherein said cancer is Plasma Cell Neoplasms:
- 1116. A method of claim 1, wherein said cancer is Plasmacytoma
- 1117. A method of claim 1, wherein said cancer is Pleomorphic Carcinoma
- 1118. A method of claim 1, wherein said cancer is Pleomorphic Liposarcoma
- 1119. A method of claim 1, wherein said cancer is Pleomorphic Rhabdomyosarcoma
- 1120. A method of claim 1, wherein said cancer is Pleura Metastases
- 1121. A method of claim 1, wherein said cancer is Pleural Effusion, Malignant
- 1122. A method of claim 1, wherein said cancer is Pleural Mesothelioma, Malignant
- 1123. A method of claim 1, wherein said cancer is Plexiform Fibrohistiocytic Tymor
- 1124. A method of claim 1, wherein said cancer is Precursor B-Lymphoblastic Lymphoma
- 1125. A method of claim 1, wherein said cancer is Preleukemia
- 1126. A method of claim 1, wherein said cancer is Primary Central Nervous System Lymphoma
- 1127. A method of claim 1, wherein said cancer is Primary Effusion Lymphoma
- 1128. A method of claim 1, wherein said cancer is Primary leptomeningeal lymphoma
- 1129. A method of claim 1, wherein said cancer is Primary Mammary Adenocarcinoma

- 1130. A method of claim 1, wherein said cancer is Primary Mediastinal (Thymic) Large B-Cell LymphomaPrimary spinal cord lymphoma
- 1131. A method of claim 1, wherein said cancer is Primary peritoneal carcinoma
- 1132. A method of claim 1, wherein said cancer is Primary Peritoneal Mesothelioma:
- 1133. A method of claim 1, wherein said cancer is Primary Peritoneal Papillary Serous Adenocarcinoma
- 1134. A method of claim 1, wherein said cancer is Primary Vaginal Melanomas
- 1135. A method of claim 1, wherein said cancer is Primitive Neuroectodermal Tumor (PNET)

  (Adult)
- 1136. A method of claim 1, wherein said cancer is Primitive Neuroectodermal Tumor (PNET) (Child)
- 1137. A method of claim 1, wherein said cancer is Prolymphocytic Leukemia
- 1138. A method of claim 1, wherein said cancer is Promyelocytic Leukemia
- 1139. A method of claim 1, wherein said cancer is Prophylactic Mastectomy
- 1140. A method of claim 1, wherein said cancer is Prostate Cancer in the Elderly
- 1141. A method of claim 1, wherein said cancer is Prostate Cancer with Bone Metastases
- 1142. A method of claim 1, wherein said cancer is Prostate Cancer, Early-Stage
- 1143. A method of claim 1, wherein said cancer is Prostate Cancer, Hormone Refractory
- 1144. A method of claim 1, wherein said cancer is Prostate Cancer, Small Cell
- 1145. A method of claim 1, wherein said cancer is Prostate Cancer, Stage A (Stage I)
- 1146. A method of claim 1, wherein said cancer is Prostate Cancer, Stage B (Stage II)
- 1147. A method of claim 1, wherein said cancer is Prostate Cancer, Stage C (Stage III)
- 1148. A method of claim 1, wherein said cancer is Prostate Cancer, Stage D (Stage IV)
- 1149. A method of claim 1, wherein said cancer is Prostate Cancer, Transitional Cell
- 1150. A method of claim 1, wherein said cancer is Prostate Cancer:
- 1151. A method of claim 1, wherein said cancer is Prostatic Intraepithelial Neoplasia (PIN)
- 1152. A method of claim 1, wherein said cancer is Protein-Losing Enteropathy
- 1153. A method of claim 1, wherein said cancer is Proximal Ductal Epithelium Adenocarcinoma
- 1154. A method of claim 1, wherein said cancer is PSA
- 1155. A method of claim 1, wherein said cancer is Pseudomyxoma Peritonei

- 1156. A method of claim 1, wherein said cancer is Pseudomyxoma Peritonei
- 1157. A method of claim 1, wherein said cancer is Pulmonary Blastoma
- 1158. A method of claim 1, wherein said cancer is Rectal Cancer with Brain Metastases
- 1159. A method of claim 1, wherein said cancer is Rectal Cancer with Liver Metastases
- 1160. A method of claim 1, wherein said cancer is Rectal Cancer, Stage I
- 1161. A method of claim 1, wherein said cancer is Rectal Cancer, Stage II
- 1162. A method of claim 1, wherein said cancer is Rectal Cancer, Stage III
- 1163. A method of claim 1, wherein said cancer is Recurrent Colon Cancer
- 1164. A method of claim 1, wherein said cancer is Recurrent Colorectal Cancer
- 1165. A method of claim 1, wherein said cancer is Recurrent Lung Cancer
- 1166. A method of claim 1, wherein said cancer is Recurrent Melanoma
- 1167. A method of claim 1, wherein said cancer is Recurrent Ovarian Cancer
- 1168. A method of claim 1, wherein said cancer is Recurrent Prostate Cancer
- 1169. A method of claim 1, wherein said cancer is Recurrent Rectal Cancer
- 1170. A method of claim 1, wherein said cancer is Relapsed Lymphoma
- 1171. A method of claim 1, wherein said cancer is Renal Cell Carcinoma
- 1172. A method of claim 1, wherein said cancer is Renal Cell Carcinoma with Lung Metastases
- 1173. A method of claim 1, wherein said cancer is Renal Pelvis Cancer
- 1174. A method of claim 1, wherein said cancer is Reticulum Cell Sarcoma (Lymphoma of bone)
- 1175. A method of claim 1, wherein said cancer is Retinoblastoma (Adult)
- 1176. A method of claim 1, wherein said cancer is Retinoblastoma (Child)
- 1177. A method of claim 1, wherein said cancer is Rhabdomyosarcoma
- 1178. A method of claim 1, wherein said cancer is Rhabdomyosarcoma
- 1179. A method of claim 1, wherein said cancer is Rhabdomyosarcoma
- 1180. A method of claim 1, wherein said cancer is Rhabdomyosarcomas
- 1181. A method of claim 1, wherein said cancer is Richter's lymphoma
- 1182. A method of claim 1, wherein said cancer is Richter's Syndrome
- 1183. A method of claim 1, wherein said cancer is Rising PSA as an Indication of Recurrent Prostate Cancer
- 1184. A method of claim 1, wherein said cancer is Salivary Gland Cancer including:

- 1185. A method of claim 1, wherein said cancer is Sarcoma
- 1186. A method of claim 1, wherein said cancer is Sarcoma of Bone
- 1187. A method of claim 1, wherein said cancer is sarcomatoid
- 1188. A method of claim 1, wherein said cancer is Sarcomatoid
- 1189. A method of claim 1, wherein said cancer is Sarcomatoid Carcinoma
- 1190. A method of claim 1, wherein said cancer is Schwannoma
- 1191. A method of claim 1, wherein said cancer is Schwannoma, Malignant
- 1192. A method of claim 1, wherein said cancer is Scirhous Patern Tumors
- 1193. A method of claim 1, wherein said cancer is Sclerosing
- 1194. A method of claim 1, wherein said cancer is Sclerosing Liposarcoma
- 1195. A method of claim 1, wherein said cancer is Sebaceous Carcinoma
- 1196. A method of claim 1, wherein said cancer is Sebaceous Carcinoma
- 1197. A method of claim 1, wherein said cancer is Serous Surface Carcinoma of the Peritoneum
- 1198. A method of claim 1, wherein said cancer is Serous Surface Papillary Carcinoma
- 1199. A method of claim 1, wherein said cancer is Sezary Syndrome
- 1200. A method of claim 1, wherein said cancer is Simple Leiomyoma
- 1201. A method of claim 1, wherein said cancer is Sinus Cancer
- 1202. A method of claim 1, wherein said cancer is Sinus Cancer, Cavernous
- 1203. A method of claim 1, wherein said cancer is Sinus Cancer, Endodermal
- 1204. A method of claim 1, wherein said cancer is Sinus Cancer, Esthesioneuroblastoma
- 1205. A method of claim 1, wherein said cancer is Sinus Cavity Cancer
- 1206. A method of claim 1, wherein said cancer is Sinus, Cavernous
- 1207. A method of claim 1, wherein said cancer is Skeletal Muscle Tumors
- 1208. A method of claim 1, wherein said cancer is Skin Cancer:
- 1209. A method of claim 1, wherein said cancer is Skin Metastases
- 1210. A method of claim 1, wherein said cancer is Small Cell Bladder Cancer
- 1211. A method of claim 1, wherein said cancer is Small Cell Carcinoma
- 1212. A method of claim 1, wherein said cancer is Small Cell Lung Cancer
- 1213. A method of claim 1, wherein said cancer is Small Cell Lung Cancer with Brain Metastases

- 1214. A method of claim 1, wherein said cancer is Small Cell Lung Cancer with Liver Metastases
- 1215. A method of claim 1, wherein said cancer is Small Cell Lung Cancer, Extensive Stage
- 1216. A method of claim 1, wherein said cancer is Small Cell Lung Cancer, Limited Stage
- 1217. A method of claim 1, wherein said cancer is Small Cell Osteosarcoma
- 1218. A method of claim 1, wherein said cancer is Small Cells
- 1219. A method of claim 1, wherein said cancer is Small Cleaved Cell Lymphoma
- 1220. A method of claim 1, wherein said cancer is Small Intestine Cancer, including:
- 1221. A method of claim 1, wherein said cancer is Small Round Cell Sarcoma
- 1222. A method of claim 1, wherein said cancer is Smooth Muscle Tumors
- 1223. A method of claim 1, wherein said cancer is Soft Tissue Lymphoma
- 1224. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma (Adult)
- 1225. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma (Child)
- 1226. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Angiosarcoma
- 1227. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Clear Cell
- 1228. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Dermatofibrosarcoma Protuberans
- 1229. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Hemangiopericytoma
- 1230. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Leiomyosarcoma
- 1231. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Liposarcoma
- 1232. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Malignant Fibrous Histiocytoma
- 1233. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Primitive Neuroectodermal (Adult)
- 1234. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Primitive Neuroectodermal (Child)
- 1235. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Rhabdomyosarcoma
- 1236. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma, Synovial
- 1237. A method of claim 1, wherein said cancer is Soft Tissue Sarcoma:
- 1238. A method of claim 1, wherein said cancer is Solitary Fibrous Tumor
- 1239. A method of claim 1, wherein said cancer is Solitary Fibrous Tumor

- 1240. A method of claim 1, wherein said cancer is Solitary Plasmacytoma
- 1241. A method of claim 1, wherein said cancer is Spinal Cord Cancer
- 1242. A method of claim 1, wherein said cancer is Spindle Cell Carcinoma
- 1243. A method of claim 1, wherein said cancer is Spindle Cell Hemangioendothelioma
- 1244. A method of claim 1, wherein said cancer is Spindle Cell Rhabdomyosarcoma
- 1245. A method of claim 1, wherein said cancer is Spindle Cell Thyroid Cancer
- 1246. A method of claim 1, wherein said cancer is Spindle Sarcomatoid Cells
- 1247. A method of claim 1, wherein said cancer is Splenic Marginal Zone Lymphoma with or without Villous Lymphocytes
- 1248. A method of claim 1, wherein said cancer is Squamous Cell
- 1249. A method of claim 1, wherein said cancer is Squamous Cell Cancer (Non-Skin)
- 1250. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma
- 1251. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma
- 1252. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma
- 1253. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma
- 1254. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma Large Call Nonkeratinizing
- 1255. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma Large Cell Keratinizing
- 1256. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma Papillary
- 1257. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma Sarcomatoid Squamous Carcinoma
- 1258. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma Small Cell Carcinoma
- 1259. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma Verrucous Carcinoma
- 1260. A method of claim 1, wherein said cancer is Squamous Cell Carcinoma:
- 1261. A method of claim 1, wherein said cancer is Squamous Cell Carcinomas Basaloid
- 1262. A method of claim 1, wherein said cancer is Squamous Cell Carcinomas Clear Cell
- 1263. A method of claim 1, wherein said cancer is Squamous Cell Carcinomas Papillary
- 1264. A method of claim 1, wherein said cancer is Squamous Cell Carcinomas Small Cell

- 1265. A method of claim 1, wherein said cancer is Squamous Cell Carcinomas:
- 1266. A method of claim 1, wherein said cancer is Squamous Cell-keratoacanthoma, periungual
- 1267. A method of claim 1, wherein said cancer is Squamous Cell Lung Cancer
- 1268. A method of claim 1, wherein said cancer is Squamous Cell Skin Cancer
- 1269. A method of claim 1, wherein said cancer is Squamous Hyperplasia
- 1270. A method of claim 1, wherein said cancer is Stem Cell Transplantation
- 1271. A method of claim 1, wherein said cancer is Stomach Cancer with Bone Metastases
- 1272. A method of claim 1, wherein said cancer is Stomach Cancer, Adenocanthoma
- 1273. A method of claim 1, wherein said cancer is Stomach Cancer, Adenocarcinoma
- 1274. A method of claim 1, wherein said cancer is Stomach Cancer, Adenosquamous Carcinoma
- 1275. A method of claim 1, wherein said cancer is Stomach Cancer, Gastric Carcinoid
- 1276. A method of claim 1, wherein said cancer is Stomach Cancer, Gastric Leiomyosarcoma
- 1277. A method of claim 1, wherein said cancer is Stomach Cancer, Gastric Lymphoma
- 1278. A method of claim 1, wherein said cancer is Stomach Cancer, Gastric Plasmacytoma
- 1279. A method of claim 1, wherein said cancer is Stomach Cancer, including:
- 1280. A method of claim 1, wherein said cancer is Stomach Cancer, Linitis Plastica
- 1281. A method of claim 1, wherein said cancer is Stomach Cancer, Mixed adeno- and Choriocarcinoma
- 1282. A method of claim 1, wherein said cancer is Stomach Cancer, Mucinous Adenocarcinoma
- 1283. A method of claim 1, wherein said cancer is Stomach Cancer, Papillary Adenocarcinoma
- 1284. A method of claim 1, wherein said cancer is Stomach Cancer, Scirrhous Carcinoma
- 1285. A method of claim 1, wherein said cancer is Stomach Cancer, Signet Ring Cell
- 1286. A method of claim 1, wherein said cancer is Stomach Cancer, Squamous Cell Carcinoma
- 1287. A method of claim 1, wherein said cancer is Storiform-Pleomorphic
- 1288. A method of claim 1, wherein said cancer is Subacute Sensory Neuronopathy and Encephalomyeloneuritis
- 1289. A method of claim 1, wherein said cancer is Subcutaneous Panniculitis-Like T-Cell Lymphoma

- 1290. A method of claim 1, wherein said cancer is Superficial Bladder Cancer
- 1291. A method of claim 1, wherein said cancer is Superficial Fibromatoses
- 1292. A method of claim 1, wherein said cancer is Sweat Glands Cancer
- 1293. A method of claim 1, wherein said cancer is Sweet's syndrome
- 1294. A method of claim 1, wherein said cancer is Syndrome of Inappropriate Antidiuretic Hormone Production
- 1295. A method of claim 1, wherein said cancer is Synovial Sarcoma
- 1296. A method of claim 1, wherein said cancer is Synovial Sarcoma
- 1297. A method of claim 1, wherein said cancer is T-Cell Leukemia
- 1298. A method of claim 1, wherein said cancer is T-Cell Lymphoma, Cutaneous
- 1299. A method of claim 1, wherein said cancer is T-Cell Lymphomas of the Small Intestine
- 1300. A method of claim 1, wherein said cancer is T-Cell-Rich/Histiocyte-Rich Large B-Cell Lymphoma
- 1301. A method of claim 1, wherein said cancer is Teratoma
- 1302. A method of claim 1, wherein said cancer is Testicular Cancer, Adenocarcinoma of the Rete Testis
- 1303. A method of claim 1, wherein said cancer is Testicular Cancer, Carcinoma In Situ
- 1304. A method of claim 1, wherein said cancer is Testicular Cancer, Choriocarcinoma
- 1305. A method of claim 1, wherein said cancer is Testicular Cancer, Epidermoid Cyst
- 1306. A method of claim 1, wherein said cancer is Testicular Cancer, Germ Cell
- 1307. A method of claim 1, wherein said cancer is Testicular Cancer, Gonadoblastoma
- 1308. A method of claim 1, wherein said cancer is Testicular Cancer, Granulosa Cell Tumors
- 1309. A method of claim 1, wherein said cancer is Testicular Cancer, Leydig Cell Tumors
- 1310. A method of claim 1, wherein said cancer is Testicular Cancer, Lymphoma
- 1311. A method of claim 1, wherein said cancer is Testicular Cancer, Mesothelioma
- 1312. A method of claim 1, wherein said cancer is Testicular Cancer, Metastatic Carcinoma
- 1313. A method of claim 1, wherein said cancer is Testicular Cancer, Non-Seminoma:
- 1314. A method of claim 1, wherein said cancer is Testicular Cancer, Sarcomas
- 1315. A method of claim 1, wherein said cancer is Testicular Cancer, Seminoma:
- 1316. A method of claim 1, wherein said cancer is Testicular Cancer, Sertoli Cell Tumors:
- 1317. A method of claim 1, wherein said cancer is Testicular Cancer, Stage I

- 1318. A method of claim 1, wherein said cancer is Testicular Cancer, Stage II
- 1319. A method of claim 1, wherein said cancer is Testicular Cancer, Stage III
- 1320. A method of claim 1, wherein said cancer is Thalamus (Thalamic) Brain Tumor
- 1321. A method of claim 1, wherein said cancer is Thymic Carcinoid
- 1322. A method of claim 1, wherein said cancer is Thymic Carcinoma
- 1323. A method of claim 1, wherein said cancer is Thymolipoma
- 1324. A method of claim 1, wherein said cancer is Thymoma
- 1325. A method of claim 1, wherein said cancer is Thymus Cancer, including:
- 1326. A method of claim 1, wherein said cancer is Thyroid Cancer:
- 1327. A method of claim 1, wherein said cancer is Thyroid Lymphoma
- 1328. A method of claim 1, wherein said cancer is Thyroid malignancy derived from follicular or parafollicular C cells
- 1329. A method of claim 1, wherein said cancer is Tongue Base Cancer
- 1330. A method of claim 1, wherein said cancer is Tongue Cancer
- 1331. A method of claim 1, wherein said cancer is Transition Cell Cancer of the Urethra
- 1332. A method of claim 1, wherein said cancer is Transitional Cell
- 1333. A method of claim 1, wherein said cancer is Transitional Cell Cancer of Renal Pelvis
- 1334. A method of claim 1, wherein said cancer is Transitional Cell Cancer of the Ureter
- 1335. A method of claim 1, wherein said cancer is Transitional Cell Carcinoma
- 1336. A method of claim 1, wherein said cancer is Transitional Cell Cencer of Bladder
- 1337. A method of claim 1, wherein said cancer is Transitional Cell Tumors
- 1338. A method of claim 1, wherein said cancer is True Leiomyoma
- 1339. A method of claim 1, wherein said cancer is Tuberous Sclerosis (Bourneville Disease)
- 1340. A method of claim 1, wherein said cancer is Tylosis
- 1341. A method of claim 1, wherein said cancer is Typical
- 1342. A method of claim 1, wherein said cancer is Unknown Primary Cancer
- 1343. A method of claim 1, wherein said cancer is Ureter Cancer
- 1344. A method of claim 1, wherein said cancer is Urethra Cancer, Carcinoma of Bulbomembranous Urethra
- 1345. A method of claim 1, wherein said cancer is Urethra Cancer, Carcinoma of Distal Urethra

- 1346. A method of claim 1, wherein said cancer is Urethra Cancer, Carcinoma of Prostatic Urethra
- 1347. A method of claim 1, wherein said cancer is Urethra Cancer, Carcinoma of Proximal Urethra
- 1348. A method of claim 1, wherein said cancer is Urethra Cancer:
- 1349. A method of claim 1, wherein said cancer is Uterine Cancer
- 1350. A method of claim 1, wherein said cancer is Uterine Cancer, Carcinosarcoma
- 1351. A method of claim 1, wherein said cancer is Uterine Cancer, Endometrial
- 1352. A method of claim 1, wherein said cancer is Uterine Cancer, Leiomyosarcoma
- 1353. A method of claim 1, wherein said cancer is Uterine Cancer, Papillary Serous
- 1354. A method of claim 1, wherein said cancer is Uterine Cancer, Sarcoma
- 1355. A method of claim 1, wherein said cancer is Uterine Cancer, Stage I
- 1356. A method of claim 1, wherein said cancer is Uterine Cancer, Stage II
- 1357. A method of claim 1, wherein said cancer is Uterine Cancer, Stage III
- 1358. A method of claim 1, wherein said cancer is Uterine Cancer, Stage IV
- 1359. A method of claim 1, wherein said cancer is Uterine Sarcoma
- 1360. A method of claim 1, wherein said cancer is Vagina Cancer:
- 1361. A method of claim 1, wherein said cancer is Vaginal Intraepithelial Neoplasia
- 1362. A method of claim 1, wherein said cancer is Verrucous carcinoma
- 1363. A method of claim 1, wherein said cancer is Verrucous Carcinoma
- 1364. A method of claim 1, wherein said cancer is Verrucous Carcinoma
- 1365. A method of claim 1, wherein said cancer is Vocal Cord Cancer
- 1366. A method of claim 1, wherein said cancer is Vulva Cancer:
- 1367. A method of claim 1, wherein said cancer is Vulvar Intraepithelial Neoplasia
- 1368. A method of claim 1, wherein said cancer is Vulvar Sarcoma
- 1369. A method of claim 1, wherein said cancer is Waldenstrom's Macroglobulinemia
- 1370. A method of claim 1, wherein said cancer is Waldenström's macroglobulinemia (WM)
- 1371. A method of claim 1, wherein said cancer is Warthin's Tumor
- 1372. A method of claim 1, wherein said cancer is Well-differentiated Liposarcoma
- 1373. A method of claim 1, wherein said cancer is Wilms' Tumor (Child)
- 1374. A method of claim 1, wherein said cancer is With Malignant Differentiation

WO 2007/053573 PCT/US2006/042367

115

1375. A method of claim 1, wherein said cancer is Yolk Sac

1376. A method of claim 1, wherein said cancer is Zollinger-Ellison Syndrome